В статьях на сайте использованы следующие сокращения:

• °F — температура по Фаренгейту
• °C — температура по Цельсию
• 5-НТ — 5-гидроксииндолуксусная кислота мочи
• АБ — антибиотик(и)
• АБЛА — аллергический бронхолегочный аспергиллез
• АБТ — антибактериальная терапия
• АВ — атриовентрикулярный
• АГ — артериальная гипертензия
• АГн — антиген
• АД — артериальное давление
• АДГ — антидиуретический гормон
• АДС — анатоксин дифтерийно-столбнячный
• АДС-М — анатоксин дифтерийно-столбнячный (малые дозы)
• АДФ — аденозиндифосфорная кислота, аденозиндифосфат
• АКДС — анатоксин коклюшно-дифтерийно-столбнячный
• АКТГ — адренокортикотропный гормон
• АКШ — аортокоронарное шунтирование
• АЛТ — аланинаминотрансфераза
• амер. — американский
• АМК — азот мочевины крови
• АМФ — аденозинмонофосфорная кислота, аденозинмонофосфат
• АНА — антинуклеарные антитела
• анат. — анатомический
• англ. — английский
• АНЦА — антинейтрофильные цитоплазматические антитела
• АПФ — ангиотензин-превращающий фермент
• АРВТ — антиретровирусная терапия
• АРП — активность ренина в плазме крови
• АСК — аминосалициловая кислота
• ACT — аспартатаминотрансфераза
• АТл — антитело
• АТФ — аденозинтрифосфорная кислота, аденозинтрифосфат
• АуД — аутосомно-доминантный
• АуР — аутосомно-рецессивный
• АФП — α-фетопротеин
• АФС — антифосфолипидный синдром
• АХЭ — ацетилхолинэстераза
• АЦХ — ацетилхолин
• АЧТВ — активированное частичное тромбопластиновое время
• БА — бронхиальная астма
• БАД — биологически активная добавка
• БАЛ — бронхоальвеолярный лаваж
• БАР — биполярное аффективное расстройство (I или II типа)
• БКК — большой круг кровообращения
• БЛНПГ — блокада левой ножки пучка Гиса
• БМСЭ — бюро медико-социальной экспертизы
• БП — брюшная полость
• БПНПГ — блокада правой ножки пучка Гиса
• БРА — блокатор рецепторов ангиотензина
• БРД - болезнь Розаи-Дорфмана
• БРМ — базовые реанимационные мероприятия
• БРНС — быстро разрешившееся необъяснимое событие
• БЦЖ — бацилла Кальметта-Герена
• в т.ч. — в том числе
• в. — век
• в/ — внутри... в сложносоставных словах (напр.
• в/сосудистый, в/черепной и т.п.)
• в/а — внутриартериально
• в/в — внутривенно
• в/к — внутрикожно
• в/м — внутримышечно
• вв. — века
• в-во — вещество
• ВБП — внебольничная пневмония
• ВВЭ — военно-врачебная экспертиза
• ВГД — внутриглазное давление
• ВГЧ — вирус герпеса человека
• ВДП — верхние дыхательные пути
• ВЖК — внутрижелудочковое кровоизлияние
• ВЗК — воспалительные заболевания кишечника
• ВЗОМТ — воспалительные заболевания органов малого таза
• ВИП — вазоактивный интестинальный пептид
• ВИЧ — вирус иммунодефицита человека
• ВМП — высокотехнологичная медицинская помощь
• ВМС — внутриматочное средство (спираль)
• ВН — вирусная нагрузка
• ВНС — вегетативная нервная система
• ВОВ — Великая Отечественная война
• ВОГМ — высокогорный отек головного мозга
• ВОЗ — Всемирная организация здравоохранения
• ВОЛ — высокогорный отек легких
• ВОМК — врач, осуществляющий медицинский контроль
• ВОП — врач общей практики
• ВПВ — верхняя полая вена
• ВПГ — вирус простого герпеса
• ВПР — врожденные пороки развития
• ВПС — врожденный порок сердца
• ВПЧ — вирус папилломы человека
• ВРТ — вспомогательные репродуктивные технологии
• ВСВИ - воспалительный синдром восстановления иммунитета
• ВСО — водно-солевой обмен
• ВЧД — внутричерепное давление
• ВЧИВЛ — высокочастотная искусственная вентиляция легких (HFV)
• ВЭБ — вирус Эпштейна-Барр
• г — грамм
• г. — год
• Г-6-ФД — глюкозо-6-фосфатдегидрогеназа
• ГАМК — гамма-аминомасляная кислота
• ГБ — гипертоническая болезнь
• ГБН — гемолитическая болезнь новорожденного
• ГБО — гипербарическая оксигенация
• ГГПТ — γ-глутамилтранспептидаза
• ГЗТ — гиперчувствительность замедленного типа
• гист. — гистологический
• ГК — грудная клетка
• ГКМП — гипертрофическая кардиомиопатия
• ГКС — глюкокортикостероид(ы)
• ГЛГ — гемофагоцитарный лимфогистиоцитоз
• ГЛПС — геморрагическая лихорадка с почечным синдромом
• ГМ — головной мозг
• ГМ-КСФ — гранулоцитарно-макрофагальный колониестимулирующий фактор
• ГМФ — гуанозинмонофосфат
• ГнРГ — гонадотропин-рилизинг-гормон
• ГНТ — гиперчувствительность немедленного типа
• ГПОД — грыжа пищеводного отверстия диафрагмы
• ГРДС — гипоксическая реакция дыхательной системы
• греч. — греческий
• ГТФ — гуанозинтрифосфат
• ГУС — гемолитико-уремический синдром
• Гц — герц
• ГЭБ — гематоэнцефалический барьер
• ГЭР — гастроэзофагеальный рефлюкс
• ГЭРБ — гастроэзофагеальная рефлюксная болезнь
• дБ — децибел
• ДВС — диссеминированное внутрисосудистое свертывание
• ДГПЖ — доброкачественная гиперплазия предстательной железы
• ДГТ — дигидротестостерон
• ДД — дифференциальная диагностика, дифференциально-диагностический
• ДДБА — длительно действующие β₂-агонисты
• ДДК — дифференциально-диагностический критерий (критерии)
• ДИ — доверительный интервал
• ДК — диагностический критерий
• ДКА — диабетический кетоацидоз
• ДКМП — дилатационная кардиомиопатия
• ДМЖП — дефект межжелудочковой перегородки
• ДМПП — дефект межпредсердной перегородки
• ДМС — добровольное медицинское страхование
• ДН — дыхательная недостаточность
• ДНК — дезоксирибонуклеиновая кислота
• ДНТ — дефекты нервной трубки
• ДОФА — дигидроксифенилаланин
• ДП — дыхательные пути
• ДПК — двенадцатиперстная кишка
• ДПМ — дата последней менструации
• ДПП — давление в правом предсердии
• др. — другие
• ДТП — дорожно-транспортное происшествие
• ДЦП — детский церебральный паралич
• ЕД — единица действия
• ЖВП — желчевыводящие пути
• ЖДА — железодефицитная анемия
• ЖЕЛ — жизненная емкость легких
• ЖКБ — желчекаменная болезнь
• ЖКК — желудочно-кишечное кровотечение
• ЖКТ — желудочно-кишечный тракт
• ЖНВЛП — жизненно необходимые и важные лекарственные препараты (список, перечень)
• ЖТ — желудочковая тахикардия
• ЗВУР — задержка внутриутробного развития
• ЗЛ — здоровые люди (лица)
• ЗНО — злокачественное новообразование
• ЗО — здравоохранение
• ЗОЖ — здоровый образ жизни
• ЗСН — застойная сердечная недостаточность
• иАПФ — ингибиторы ангиотензин-превращающего фермента
• ИБС — ишемическая болезнь сердца
• ИВЛ — искусственная вентиляция легких
• ИГКС — ингаляционные глюкокортикостероиды
• ИЗЛ — интерстициальные заболевания легких
• ИКД — имплантируемый кардиовертер-дефибриллятор
• ИКП — иммунокомпрометированные пациенты
• ИЛ — интерлейкин
• ИЛДБ — интегрированное лечение детских болезней
• ИМ — инфаркт миокарда
• ИМАО — ингибитор(ы) моноаминоксидазы
• ИМбпБТ — инфаркт миокарда без подъема сегмента ST
• ИМП — инфекция мочевых (мочевыводящих) путей
• ИМпST — инфаркт миокарда с подъемом сегмента ST
• ИМТ — индекс массы тела
• ИОЛ — интраокулярная линза
• ИПП — ингибиторы протонной помпы (протонного насоса)
• ИППП — инфекции, передаваемые половым путем
• ИСС — индивидуальные спасательные средства
• истор. — историческое
• итал. — итальянский
• ИТП — идиопатическая тромбоцитопеническая пурпура
• ИТШ — инфекционно-токсический шок
• ИФА — иммуноферментный анализ
• КА — коронарная(ые) артерия(и)
• КАГ — коронарография
• КБМП - качество и безопасность медицинской помощи
• кВ — киловольт
• кг — килограмм
• КДАИ - Clostridium difficile-ассоциированная инфекция
• КДБА — короткодействующие β2-агонисты
• КДД — конечно-диастолическое давление
• КДО — конечно-диастолический объем
• КДР — конечно-диастолический размер
• кит. — китайский
• ккал — килокалория
• кл. — клетки, клеток
• КМП — качество медицинской помощи
• КоА — коэнзим А, кофермент А
• КОЕ — колониеобразующая единица
• КОК — комбинированные оральные контрацептивы
• КПТ — когнитивно-поведенческая терапия
• КР — клинические рекомендации
• КСД — конечно-систолическое давление
• КСО — конечно-систолический объем
• КСР — конечно-систолический размер
• КТ — компьютерная томография
• КТВР — компьютерная томография высокого разрешения
• КТГ — кардиотокография
• КФК — креатинфосфокиназа
• КЩС — кислотно-щелочное состояние
• л — литр
• л/о — ложноотрицательный
• л/п — ложноположительный
• ЛА — легочная артерия
• ЛАГ — легочная артериальная гипертензия лат. — латинский
• ЛГ — лютеинизирующий гормон
• ЛДГ — лактатдегидрогеназа
• ЛЖ — левый желудочек
• ЛЖВ - людей, живущих с ВИЧ
• ЛОР — имеющий отношение к оториноларингологии (ЛОР-врач, ЛОР-органы)
• ЛП — лекарственный препарат
• ЛПВП — липопротеины высокой плотности
• ЛПНП — липопротеины низкой плотности
• ЛПОНП — липопротеины очень низкой плотности
• ЛПУ — лечебно-профилактическое учреждение ЛС — лекарственное средство
• ЛУ — лимфатический(ие) узел(лы)
• ЛФК — лечебная физкультура
• м.б. — может (мог, могут, могли) быть
• М/Ж — соотношение мужчин и женщин
• максД — максимальная доза
• максНД — максимальная начальная доза
• максРД — максимальная разовая доза
• максСД — максимальная суточная доза
• МАНК — метод амплификации нуклеиновых кислот
• МАО — моноаминоксидаза
• МВП — мочевыводящие пути
• мг — миллиграмм
• МДБ — мышечная дистрофия Беккера
• МДД — мышечная дистрофия Дюшенна
• МДМА — метилендиоксиметамфетамин
• ME — международная единица
• мед. — медицинский
• мес — месяц
• МЖ — молочная железа
• МЖП — межжелудочковая перегородка
• М3 — министерство здравоохранения
• мин — минут(а)
• минД — минимальная доза
• минСД — минимальная суточная доза
• МКБ — мочекаменная болезнь
• МКБ-10 — Международная классификация болезней 10-го пересмотра
• МКБ-11 —Международная классификация болезней 11-го пересмотра
• мкВ — микровольт
• мкг — микрограмм
• МКК — малый круг кровообращения
• мкл — микролитр
• мл — миллилитр
• млн — миллион
• млрд — миллиард
• мм — миллиметр
• мм рт.ст. — миллиметр ртутного столба
• ммоль — миллимоль
• МНН — международное непатентованное наименование
• МНО — международное нормализованное отношение
• МО — медицинская организация
• МП — медицинская помощь
• МПН — миелопролиферативные новообразования
• МПС — мочеполовая система
• МР — магнитно-резонансный
• МР-венография — МРТ вен и синусов головного мозга
• мРНК — матричная РНК
• МРТ — магнитно-резонансная томография
• МРХПГ — магнитно-резонансная холангиопанкреатография
• мс — миллисекунда
• МСКТ — мультиспиральная компьютерная томогра-
• фия
• МСЭ — медико-социальная экспертиза
• МТ — масса тела
• мтДНК — митохондриальная дезоксирибонуклеиновая кислота
• МТР — масса тела при рождении
• н.э. — нашей эры
• НА — нервная анорексия
• НАД — никотинамидадениндинуклеотид
• НАДН — никотинамидадениндинуклеотид (восстановленный)
• НАДФ — никотинамидадениндинуклеотидфосфат
• НАЖБП — неалкогольная жировая болезнь печени напр. — например
• НАСГ — неалкогольный стеатогепатит
• НБ — нервная булимия
• НДО — негативный детский опыт
• нед — недели
• нем. — немецкий
• НИВЛ — неинвазивная вентиляция легких
• НЛР — нежелательная лекарственная реакция
• нм — нанометр
• НМГ — низкомолекулярный гепарин
• НМИЦ — национальный медицинский исследовательский центр
• НМП — неотложная медицинская помощь
• НМТ — низкая масса тела
• НПА — нормативно-правовой акт
• НПВ — нижняя полая вена
• НПВС — нестероидные противовоспалительные средства
• НС — нервная система
• НСГ — нейросонография
• НЭК — некротический энтероколит
• НЯК — неспецифический язвенный колит
• ОАК — общий анализ крови
• ОАМ — общий анализ мочи
• ОАП — открытый артериальный проток
• ОБП — органы брюшной полости
• ОГБ — острая горная болезнь
• ОГМ — отек головного мозга
• ОДН — острая дыхательная недостаточность
• ОДП — обструкция дыхательных путей
• ОЖСС — общая железосвязывающая способность сыворотки
• ОЗ — организация здравоохранения
• ок. — около
• ОКР — обсессивно-компульсивное расстройство
• ОКС — острый коронарный синдром
• ОЛЛ — острый лимфобластный лейкоз
• ОМП - оказание медицинской помощи
• ОМС — обязательное медицинское страхование
• ОМТ — органы малого таза
• ОНМК — острое нарушение мозгового кровообращения
• ОНМП — отделение неотложной (медицинской) помощи
• ОНМТ — очень низкая масса тела
• ООЗ — органы (организации/управления) здравоохранения
• ООЛ — остаточный объем легких
• ООН — Организация Объединенных Наций
• ОПЖ — ожидаемая продолжительность жизни
• ОПН — острая почечная недостаточность
• ОПП — острое повреждение почек
• ОПСС — общее периферическое сосудистое сопротивление
• ОРВИ — острая респираторная вирусная инфекция
• ОРДС — острый респираторный дистресс-синдром
• ОРЗ — острое респираторное заболевание
• ОРИТ — отделение реанимации и интенсивной терапии (ICU)
• ОСВО — общее содержание воды в организме
• ОФВ — объем форсированного выдоха
• ОФВ₁ — объем форсированного выдоха за 1-ю секунду
• ОЦК — объем циркулирующей крови
• п.з. — поле зрения (микроскопа)
• п/к — подкожно
• ПАВ — психоактивные вещества
• ПВ — протромбиновое время
• ПВК — периферический венозный катетер
• ПВЛ — перивентрикулярная лейкомаляция
• Пг — простагландин
• ПГГ — программа государственных гарантий оказания гражданам РФ бесплатной медицинской помощи
• ПДКВ — положительное давление конца выдоха (PEEP)
• ПЖ — правый желудочек
• ПЖЖ — поджелудочная железа
• ПЖК — подкожная жировая клетчатка (гиподерма)
• ПИ - полицитемию истинную
• ПКА — почечный канальцевый ацидоз
• ПКМД — поясно-конечностная мышечная дистрофия
• ПЛСГ — пятнистая лихорадка Скалистых гор
• ПМДР — предменструальное дисфорическое расстройство
• ПМК — пролапс митрального клапана
• ПМС — предменструальный синдром
• ПМФ — первичный миелофиброз
• ПМСП — первичная медико-санитарная помощь
• ПНА — передняя нисходящая артерия
• ПНЖК — полиненасыщенные жирные кислоты
• ПОРИТ — педиатрическое отделение реанимации и интенсивной терапии
• ПОТ — постуральная ортостатическая тахикардия
• ППВ — пневмококковая полисахаридная вакцина
• ППОАК — прямые пероральные антикоагулянты ППТ — площадь поверхности тела
• ПСА — простатоспецифический антиген
• ПСВ — пиковая скорость выдоха
• ПСВХ — прогрессирующий семейный внутрипеченочный холестаз
• ПТ — психотерапия
• ПТВ — протромбиновое время
• ПТГ — паратиреоидный гормон
• ПТИ — протромбиновый индекс
• ПТСР — посттравматическое стрессовое расстройство
• ПФЭ — пищевой фолатный эквивалент
• ПЦР — полимеразная цепная реакция
• ПШГ — пурпура Шенлейна-Геноха
• ПЩЖ — паращитовидные железы
• ПЭТ — позитронно-эмиссионная томография р/ —раз в ... (с, мин, ч, сут и т.п.)
• РА — ревматоидный артрит
• РААС — ренин-ангиотензин-альдостероновая система
• разг. — разговорный
• разл. — различный
• РАС — расстройство аутистического спектра
• РДС — респираторный дистресс-синдром
• рим. — римский
• РИФ — реакция иммунофлюоресценции
• РКИ — рандомизированные клинические исследования
• РКМП — рестриктивная кардиомиопатия
• РИГА — реакция непрямой гемагглютинации
• РНК — рибонуклеиновая кислота
• РОГК — рентгенография (рентгенограмма) органов грудной клетки
• РОЛСНС — рекомендации по оценке и лечению при сортировке в неотложных ситуациях
• РИГА — реакция прямой гемагглютинации
• р-р — раствор
• р-ритель — растворитель
• РРК — рецепторы ретиноевой кислоты
• РРМ — расширенные реанимационные мероприятия
• РСВ — респираторно-синцитиальный вирус
• РСД — расстройство стереотипных движений
• РСК — реакция связывания комплемента
• РТГА — реакция торможения гемагглютинации
• РТНГА — реакция торможения непрямой гемагглютинации
• РФ — Российская Федерация
• РХР — ретиноевые Х-рецепторы
• РЧА — радиочастотная абляция
• РЭС — ретикулоэндотелиальная система
• с — секунда
• св-во — свойство
• СВДС — синдром внезапной детской смерти
• СГЯ — синдром гиперстимуляции яичников
• СД — сахарный диабет
• СД-1 — сахарный диабет 1 -го типа
• СД-2 — сахарный диабет 2-го типа
• СДВГ — синдром дефицита внимания и гиперактивности
• СЕ — субъединица
• СЖК — свободные жирные кислоты
• СЗСТ — системное(ые) заболевание(я) соединительной ткани
• СИЗ — средства индивидуальной защиты
• СИОЗС — селективный ингибитор обратного захвата серотонина
• СИОЗСН — селективные ингибиторы обратного захвата серотонина и норэпинефрина
• СКА — серповидно-клеточная анемия
• СКВ — серповидно-клеточная болезнь
• СКВ — системная красная волчанка
• СКФ — скорость клубочковой фильтрации
• СЛР — сердечно-легочная реанимация
• см — сантиметр
• см вод.ст. — сантиметр водяного столба
• СМЖ — спинномозговая жидкость
• СМИ — средства массовой информации
• СМО — страховая медицинская организация
• СМП — скорая медицинская помощь
• СМЭ — судебно-медицинская экспертиза
• СН — сердечная недостаточность
• СНСАДГ — синдром неадекватной секреции АДГ
• СОАС — синдром обструктивного апноэ сна (во сне)
• совр. — современный
• СОЭ — скорость оседания эритроцитов
• СПИД — синдром приобретенного иммунодефицита
• СПКЯ — синдром поликистозных яичников
• СПОН — синдром полиорганной недостаточности
• СРБ — С-реактивный белок
• СРК — синдром раздраженного кишечника
• СрСД — средняя суточная доза
• ССВ — синдром Стерджа-Вебера
• ССВР — синдром системной воспалительной реакции
• ССЗ — сердечно-сосудистые заболевания
• ССС — сердечно-сосудистая система
• СССУ — синдром слабости синусового узла
• СТ — Синдром Туретта
• СТГ — соматотропный гормон
• СТР — стойкое (хроническое) моторное или вокальное тикозное расстройство
• сут — сутки
• СХУ — синдром хронической усталости
• т.д. — так далее
• т.е. — то есть
• т.к. — так как
• т.о. — таким образом
• т.п. — тому подобное
• Т3 — трийодтиронин
• Т4 — тироксин
• ТАНК — тест амплификации нуклеиновых кислот
• ТБС — тазобедренный сустав
• ТГВ — тромбоз глубоких вен
• ТГСК — трансплантация гемопоэтических стволовых клеток
• ТИА — транзиторная ишемическая атака
• ТИАБ — тонкоигольная аспирационная биопсия
• ТМО — твердая мозговая оболочка
• TH — торговое наименование лекарственных средств
• ТПГГ — территориальная программа государственных гарантий оказания гражданам РФ бесплатной медицинской помощи
• ТПМ — травматическое повреждение мозга
• ТТ — температура тела
• ТТГ — тиреотропный гормон
• ТФР — трансформирующий фактор роста
• ТЦА — трициклические антидепрессанты
• тыс. — тысяча
• ТЭД —транзиторная эритробластопения детского возраста
• ТЭЛА — тромбоэмболия легочной артерии
• ТЭО — тромбоэмболические осложнения
• УЗДС — ультразвуковое дуплексное сканирование
• УЗИ — ультразвуковое исследование
• устар. — устаревший
• УФ — ультрафиолетовый
• УФО — ультрафиолетовое облучение
• ФАП — фельдшерско-акушерский пункт
• ФВ — фракция выброса
• ФВД — функции внешнего дыхания
• ФЖ — фибрилляция желудочков
• ФЖЕЛ — форсированная жизненная емкость легких
• ФЗ — Федеральный закон
• физиол. — физиологический
• ФК — функциональный класс
• ФКС — фиброколоноскопия
• ФКУ — фенилкетонурия
• ФН — физическая нагрузка
• ФНО — фактор некроза опухоли
• ФОМС — федеральный фонд обязательного медицинского страхования
• ФОС — фосфорорганические соединения
• ФП — фибрилляция предсердий
• фр. — французский
• ФСГ — фолликулостимулирующий гормон
• ФСГС — фокально-сегментарный гломерулосклероз
• ФЭГДС — фиброэзофагогастродуоденоскопия
• ХБП — хроническая болезнь почек
• ХГЧ — хорионический гонадотропин человека
• ХДН — хроническая дыхательная недостаточность
• хим. — химический
• ХНЗЛ — хронические неспецифические заболевания легких
• ХОБЛ — хроническая обструктивная болезнь легких
• ХПН — хроническая почечная недостаточность
• ХС — холестерин
• ХСН — хроническая сердечная недостаточность
• XT — химиотерапия
• ЦВБ - цереброваскулярные болезни
• ЦВД — центральное венозное давление
• ЦБК — центральный венозный катетер
• ЦИК — циркулирующие иммунные комплексы
• ЦМВ — цитомегаловирус
• ЦНС — центральная нервная система
• ЦОГ — циклооксигеназа
• ЦПД — церебральное перфузионное давление
• ЦСТС — церебральный сольтеряющий синдром
• ч — час
• ЧД — частота дыхания
• ЧДД — частота дыхательных движений
• ЧКВ — чрескожное коронарное вмешательство
• ЧМН — черепно-мозговые нервы
• ЧМТ — черепно-мозговая травма
• ЧН — черепные нервы
• ЧС — чувствительность/специфичность (ЧС 97%/87%)
• ЧСС — частота сердечных сокращений
• ЧТВ — частичное тромбопластиновое время
• ШКГ — шкала комы Глазго
• ШОП — шейный отдел позвоночника
• ЩЖ — щитовидная железа
• ЩФ — щелочная фосфатаза
• ЭАР — эквивалент активности ретинола
• ЭГДС — эзофагогастродуоденоскопия
• ЭДТА — этилендиаминтетрауксусная кислота (этилендиаминтетраацетат)
• ЭКГ — электрокардиография
• ЭКМО — экстракорпоральная мембранная оксигенация
• ЭКО — экстракорпоральное оплодотворение
• ЭКС — электрокардиостимулятор, элекгрокардиостимуляция
• ЭМГ — электромиография
• ЭМК — электронная медицинская карта
• ЭМП — экстренная медицинская помощь
• ЭНМП — экстренная и неотложная медицинская помощь
• ЭНМТ — экстремально низкая масса тела
• ЭРХПГ —эндоскопическая ретроградная холангиопанкреатография
• ЭТ — эссенциальная тромбоцитемия
• ЭТТ — эндотрахеальная трубка
• ЭхоКГ — эхокардиография
• ЭЭГ — электроэнцефалография
• ЮДМ — ювенильный дерматомиозит
• ЮИА — ювенильный идиопатический артрит
• ЯБ — язвенная болезнь
• АА — амилоид A (amyloid А)
• ААР — Американская академия педиатрии (American Academy of Pediatrics)
• AASLD — Американская ассоциация по изучению заболеваний печени (American Association for the Study of Liver Diseases)
• ABC — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение» (Airways-Breathing-Circulation)
• АВСАЗ — белковый член АТФ-связывающей кассеты АЗ
• АВСВ11 —ген АТФ-связывающей кассеты, 11-й член подсемейства В (ATP-binding cassette, subfamily В member 11)
• АВСВ4 — ген АТФ-связывающей кассеты, 4-й член подсемейства В (ATP-binding cassette 4 gene)
• АВСС2 — ген, кодирующий 2-й член подсемейства С АТФ-связывающих кассет (ATP-binding cassette sub-family С member 2)
• ABCDE — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение-не-врологический статус-внешний вид» (Airways-Breathing-Circulation-Disability-Exposure)
• ABCG5/G8 — гетеродимер переносчика АТФ-связывающей кассеты ABCG5 и ABCG8 (heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
• AC — до еды (при назначениях) — ante cibum
• АСЕР — Американская коллегия врачей неотложной помощи (American College of Emergency Physicians)
• ACOG — Американская коллегия акушеров и гинекологов (American College of Obstetricians and Gynecologists)
• AHA — Американская кардиологическая ассоциация (American Heart Association)
• ALTE — очевидное опасное для жизни событие (apparent life-threatening event)
• ANP — предсердный натрийуретический пептид (atrial natriuretic peptide)
• APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
• ARPKD — аутосомно-рецессивный поликистоз почек ASCVD-риск — риск развития атеросклеротического сердечно-сосудистого заболевания (Arteriosclerotic Cardiovascular Disease)
• AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
• BCS — митохондриальный шаперон BCS1 (mitochondrial chaperone BCS1)
• BIN — биноминальная номенклатура живой природы
• B(i)PAP — режим искусственной вентиляции легких с двумя уровнями положительного давления (bilevel positive airway pressure)
• BNP — мозговой натрийуретический пептид В-типа [В (brain)-type natriuretic peptide]
• BRUE — быстро разрешившиеся необъяснимые события (brief resolved unexplained events)
• BSEP — насос выведения солей желчных кислот (bile salt export pump)
• CADASIL — церебральная аутосомно-доминантная артериопатия с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
• CAPS — криопирин-ассоциированный периодический синдром (cryopyrin-associated periodic syndrome)
• CBIT — комплексное поведенческое воздействие при тиках (comprehensive behavioral intervention for tics)
• CD — кластеры дифференцировки (clusters of differentiation)
• CDC — Центр по контролю и профилактике заболеваний, США (Center for Disease Control and Prevention)
• CDG — врожденные нарушения гликозилирования (congenital disorder of glycosylation)
• CFTR — трансмембранный регулятор муковисцидоза (cystic fi brosis transmembrane regulator)
• CH — гемолитический комплемент (hemolytic complement)
• CLLS — шкала оценки острой горной болезни озера Луиз у детей (Children’s Lake Louise Score)
• сМОАТ — каналикулярный мультиспецифический органический анионный транспортер (canalicular multispecific organic anion transporter)
• CMT — Шарко-Мари-Тута болезнь (Charcot-Marie-Tooth disease)
• CPAP — постоянное положительное давление в дыхательных путях (constant positive airway pressure)
• CTLA — цитотоксический Т-лимфоцитарный антиген (cytotoxic T-lymphocytic antigen)
• CYP — цитохром общий
• DAF — фактор ускорения распада (decay-accelerating factor)
• DAMP — рецепторы молекулярного фрагмента, ассоциированного с повреждением (damage-associated molecular pattern)
• DASH — диетические подходы к борьбе с гипертонией (dietary approaches to stop hypertension)
• DGAT1 — диацилглицерин-1-ацилтрансфераза (diacylglycerol acyltransferase 1)
• DHR — дигидрородамин (dihydrorhodamine)
• DSM — Диагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
• EAST syndrome — эпилепсия, атаксия, сенсоневральная тугоухость и тубулопатия (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
• EBM — доказательная медицина (evidance based medicine)
• EPCAM — молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
• ESC — Европейское общество кардиологии (European Society of Cardiology)
• EXIT — лечение плода вне матки во время родов (ех utero intrapartum treatment)
• FcRs — Fc-рецепторы — белок, расположенный на поверхности нескольких видов клеток иммунной системы (естественных киллеров, макрофагов, нейтрофилов и тучных клеток) FDA — Комитет по контролю за лекарственными веществами и пищевыми добавками, США (Food and Drug Administration)
• FFR — фракционный резерв кровотока (fractional flow reserve)
• FGF-23 — фактор роста фибробластов-23 (fibroblast growth factor-23)
• FIC 1 —семейный внутрипеченочный холестаз 1-го типа, болезнь Байлера (familial intrahepatic cholestasis)
• FiO₂ — фракция кислорода (во вдыхаемом воздухе, газовой смеси)
• FISH — флуоресцентная in situ гибридизация (fluorescence in situ hybridization)
• FLAIR — восстановление инверсии с ослаблением жидкости (fluid-attenuated inversion recovery)
• FMF — семейная средиземноморская лихорадка (familial mediterranean fever)
• FODMAP — ферментируемые олиго-, ди-, моносахариды и полиолы (fermentable oligo-, di-, monosaccharides and polyols)
• FoxP3 —транскрипционный фактор семейства Forkhead Р3
• GATA — gata-связывающий белок
• DVL — трансплантат против лейкоза (graft versus leukemia)
• HADH — гидроксилацил-КоА-дегидрогеназа (Hydroxyacyl-Coenzyme A dehydrogenase)
• HAV — вирус гепатита В (hepatitis A virus)
• Hb — гемоглобин
• HBcAg — сердцевинный антиген вируса гепатита В HBeAg — антиген вируса гепатита В
• HBsAg — поверхностный антиген вируса гепатита В
• HBV — вирус гепатита В (hepatitis В virus)
• HCV — вирус гепатита С (hepatitis С virus)
• HDV — вирус гепатита D (hepatitis D virus)
• HELLP — HELLP-синдром (гемолиз, повышенный уровень печеночных ферментов, низкий уровень тромбоцитов) (hemolysis, elevated liver enzymes, low platelets)
• HEV — вирус гепатита E (hepatitis E virus)
• HFNC — назальные канюли высокого потока (heated, high-flow nasal cannula)
• Hib — гемофильная палочка типа В (Haemophilus influenzae В type)
• HLA — лейкоцитарные антигены (главного комплекса гистосовместимости) человека (human leukocyte antigens)
• HR — отношение рисков (hazard ratio)
• HRT — терапия отмены привычки (habit reversal therapy)
• Ht — гематокрит
• HTLV — Т-лимфотропный вирус человека (human T-lymphotropic virus)
• IFN — интерферон
• Ig — иммуноглобулин
• IgA — иммуноглобулин A
• IgE — иммуноглобулин E
• IgG — иммуноглобулин G
• IgM — иммуноглобулин M
• IL — интерлейкин
• IPEX — Х-сцепленный синдром иммунной дисрегуляции, полиэндокринопатии и энтеропатии (immunedysregulation polyendocrinopathy enteropathy, X-linked)
• IQ — коэффициент умственного развития (intelligence quotient)
• JAK — янус-киназа (janus kinase)
• LFA — антиген, активирующий функцию лейкоцитов (lymphocyte function-associated antigen)
• LT — лейкотриен
• MALT — лимфоидная ткань слизистой оболочки (mucosa-associated lymphoid tissue)
• MASP — МСЛ-ассоциированная сериновая протеаза (MBL-associated serine protease)
• MBL — маннозосвязывающий лектин (mannose-binding lectin)
• MCP — мембранный белок-кофактор (membrane cofactor protein)
• MDR3 — белок множественной лекарственной устойчивости 3 (multidrug resistance protein 3)
• MELAS — митохондриальная энцефалопатия, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
• MELD — модель для оценки терминальной стадии заболеваний печени, предназначена для оценки относительной тяжести заболевания и прогноза жизни у пациентов с терминальной стадией печеночной недостаточности (ожидающих трансплантации печени) (model for end-stage liver disease)
• MERRF — миоклоническая эпилепсия с рваными красными волокнами (myoclonic epilepsy with ragged red fibers)
• MHC — главный комплекс гистосовместимости (major histocompatibility complex)
• Mr — кажущаяся молекулярная масса
• MRP — белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
• MRSA — метициллинрезистентный золотистый стафилококк
• MSSA — метициллинчувствительный золотистый стафилококк
• mTOR — мишень рапамицина у млекопитающих (mammalian target of rapamycin)
• NB! — важно, обратить внимание (nota bene)
• NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
• NK — естественные клетки-киллеры (natural killer) NMDA — И-метил-В-аспартат (N-methyl-D-aspartate)
• NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (number need to treatment)
• OR — отношение шансов (odds ratio)
• paCO₂ — парциальное давление углекислого газа в артериальной крови
• PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
• PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
• PANS — острый нейропсихиатрический синдром в детском возрасте (pediatric acute-onset neuropsychiatric syndrome)
• paO₂ — парциальное давление кислорода в артериальной крови
• PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
• PC — после еды (при назначениях) (post cibum) рСО₂ — парциальное давление углекислого газа
• PCSK-9 — пропротеиновая конвертаза субтилизинкексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
• PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (periodic fevers with aphthous stomatitis, pharyngitis and adenitis)
• PFIC — семейный внутрипеченочный холестаз (familial intrahepatic cholestasis)
• Pg — простагландин
• pH — водородный показатель
• PIM — показатель летального исхода у детей (pediatric index of mortality)
• piO₂ — парциальное давление кислорода во вдыхаемом воздухе
• рО₂ — парциальное давление кислорода
• POLG — субъединица ДНК-полимеразы γ
• PRISA II — оценка риска госпитализации у детей II (pediatric risk of admission)
• PRISM — риск летального исхода у детей (pediatric risk of mortality)
• PRN — при (по) необходимости (pro re nata — при возникновении обстоятельств)
• PRSS — ген сериновой протеазы
• PS — примечание (post scriptum)
• PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
• Q#H — каждые # часов (при назначениях) (quaque... hora)
• QAM — каждое утро (при назначениях) (quaque ante meridiem)
• QPM — каждый вечер (при назначениях) (quaque post meridiem)
• RAG — ген, активирующий рекомбиназу
• RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
• RF — ревматоидный фактор
• Rh — резус(-фактор)
• Rh«-» — резус-отрицательн(ый)
• Rh«+» — резус-положительн(ый)
• ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
• ROMK — почечный наружный мозговой калиевый канал (renal outer medullary К)
• RR — относительный риск (relative risk или risk ratio)
• RW — реакция Вассермана (reaction of Wassermann)
• SaO₂ — сатурация артериальной крови кислородом
• SatO₂ — насыщение крови кислородом
• ScvO₂ — насыщение кислородом центральной венозной крови (central venous oxygen saturation)
• SD — стандартное отклонение (standart deviation)
• SFTPA — ген сурфактантного белка A
• SFTPB — ген сурфактантного белка В
• SFTPC — ген сурфактантного белка С
• SPINK — ингибитор сериновой протеазы (serine protease inhibitor kazal)
• SpO₂ — насыщение (сатурация) гемоглобина кислородом
• spp. — виды (при родовом имени микроорганизмов)
• Src. — источник информации, библиографическая ссылка (source)
• STAT1 — сигнальный преобразователь и активатор транскрипции 1 (signal transducer and activator of transcription)
• TA — Международная анатомическая терминология
• TCR — Т-клеточный рецептор (T-cell receptor)
• TIPS —трансъюгулярный внутрипеченочный портосистемный шунт; малоинвазивная хирургическая операция, проводимая под контролем рентгеноскопии (transjugular intrahepatic portosystemic shunt)
• TLR — Толл-подобный рецептор (Toll-like receptor)
• TNF — фактор некроза опухоли (tumor necrosis factor)
• TORCH — токсоплазмоз, краснуха, цитомегаловирусная инфекция, герпес и другие инфекции (toxoplasmosis, other infections, rubella, cytomegalovirus herpes simplex)
• TPM — мутация тропомиозина (mutation of the tropomyosin)
• TRAP — синдром обратной артериальной перфузии близнецов (twin reversed arterial perfusion)
• TRAPS — периодический синдром, ассоциированный с рецептором фактора некроза опухоли (tumor necrosis factor receptor-associated periodic syndrome)
• TRPM — катионный канал с транзиторным рецепторным потенциалом, подсемейство М (transient receptor potential cation channel, subfamily M)
• VEGF — фактор роста эндотелия сосудов (vascular endothelial growth factor)
• VO₂ — потребление кислорода
• WPW — синдром Вольфа-Паркинсона-Уайта (Wolff-Parkinson-White)
• XLA — Х-сцепленная агаммаглобулинемия (X-linked agammaglobulinemia)
• αDG-RD — дистрофии, связанные с α-дистрогликанами (alpha dystroglycan-related dystrophies)
• β-ХГЧ — β-субъединица хорионического гонадотропина человека

В ходе подготовки статей по заболеваниям нервной системы в терапии для пользователей сайта МедУнивер использованы труды следующих авторов:

1. A1. Dussourd L, Martinon B, Candille C, et al. Ultrasonography helps emergency physician identify the best lumbar puncture site under the conus medullaris. Scand J Trauma Resusc Emerg Med. 2017;25:1-3.
2. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018;391:1197-1204.
3. Lehn A, Gelauff J, Hoeritzauer I, et al. Functional neurological disorders: mechanisms and treatment. J Neurol. 2016;263:611-620.
4. Ropper AE, Ropper AH. Acute spinal cord compression. N Engl J Med. 2017;376:1358-1369.
5. Schott JM. The neurology of ageing: what is normal? Pract Neurol. 2017;17:172-182.
6. Whitman GT. Examination of the patient with dizziness or imbalance. Med Clin North Am. 2019;103:191-201.
7. Fife TD. Dizziness in the outpatient care setting. Continuum (Minneap Minn). 2017;23:359-395.
8. Baker JM. Gait disorders. Am J Med. 2018;131:602-607.
9. Page-Wilson G, Wardlaw SL, Nguyen KT, et al. Evaluation of pain and stress in healthy volunteers undergoing research lumbar punctures. Neurology. 2016;87:438-439.
10. Perry JJ, Alyahya B, Sivilotti ML, et al. Differentiation between traumatic tap and aneurysmal subarachnoid hemorrhage: prospective cohort study. BMJ. 2015;350:1-7.
11. Teunissen CE, Verheul C, Willemse EAJ. The use of cerebrospinal fluid in biomarker studies. Handb Clin Neurol. 2017;146:3-20.
12. Glimoker M, Sj?lin J, ?kesson S, et al. Lumbar puncture performed promptly or after neuroimaging in acute bacterial meningitis in adults: a prospective national cohort study evaluating different guidelines. Clin Infect Dis. 2018;66:321-328.
13. Wagner K, Springer B, Pires VP, et al. Pathogen identification by multiplex LightMix real-time PCR assay in patients with meningitis and culture-negative cerebrospinal fluid specimens. J Clin Microbiol. 2018;56:1-8.
14. Viloria Alebesque A, Lopez Bravo A, Bellosta Diago E, et al. Usefulness of electroencephalography for the management of epilepsy in emergency departments. Neurologia. 2019;34:215-223.
15. Beniczky S, Conradsen I, Henning O, et al. Automated real-time detection of tonic-clonic seizures using a wearable EMG device. Neurology. 2018;90:e428-e434.
16. Domkundwar S, Autkar G, Khadilkar SV, et al. Ultrasound and EMG-NCV study (electromyography and nerve conduction velocity) correlation in diagnosis of nerve pathologies. J Ultrasound. 2017;20: 111-122.
17. Lascano AM, Lalive PH, Hardmeier M, et al. Clinical evoked potentials in neurology: a review of techniques and indications. J Neurol Neurosurg Psychiatry. 2017;88:688-696.
18. Kellogg M, Liang CW, Liebeskind DS. Sudden neurologic deficit. Handb Clin Neurol. 2016;136: 857-872.
19. Radue EW, Weigel M, Wiest R, et al. Introduction to magnetic resonance imaging for neurologists. Continuum (Minneap Minn). 2016;22:1379-1398.
20. Gibson LM, Paul L, Chappell FM, et al. Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis. BMJ. 2018;363:1-10.
21. Qaseem A, Barry MJ, Kansagara D. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164:350-359.
22. Gartlehner G, Gaynes BN, Amick HR, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016; 164:331-341.
23. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357-1366.
24. Cuijpers P, Sijbrandij M, Koole SL, et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13:56-67.
25. Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:1-10.
26. Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150-158.
27. Richards DA, Ekers D, McMillan D, et al. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016;388:871-880.
28. Grochtdreis T, Brettschneider C, Wegener A, et al. Cost-effectiveness of collaborative care for the treatment of depressive disorders in primary care: a systematic review. PLoS ONE. 2015;10:1-19.
29. McGirr A, V?hringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomized placebo-controlled trials. Lancet Psychiatry. 2016;3:1138-1146.
30. Chiang KJ, Tsai JC, Liu D, et al. Efficacy of cognitive-behavioral therapy in patients with bipolar disorder: a meta-analysis of randomized controlled trials. PLoS ONE. 2017;12:1-19.
31. Cuijpers P, Sijbrandij M, Koole S, et al. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34:130-140.
32. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393:768-777.
33. Reiter K, Andersen SB, Carlsson J. Neurofeedback treatment and posttraumatic stress disorder: effectiveness of neurofeedback on posttraumatic stress disorder and the optimal choice of protocol. J Nerv Ment Dis. 2016;204:69-77.
34. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71:681-688.
35. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-962.
36. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686-693.
37. Nometh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389:1103-1113.
38. Gandal MJ, Haney JR, Parikshak NN, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science. 2018;359:693-697.
39. Stewart DE. Vigod S. Postpartum depression. N Engl J Med. 2016;375:2177-2186.
40. Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299-2312.
41. Park LT, Zarate CA Jr. Depression in the primary care setting. N Engl J Med. 2019;380:559-568.
42. Scott J, Murray G, Henry C, et al. Activation in bipolar disorders: a systematic review. JAMA Psychiatry. 2017;74:189-196.
43. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387:1561-1572.
44. Shine B, McKnight RF, Leaver L, et al. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386:461-468.
45. Craske MG, Stein MB. Anxiety. Lancet. 2016;388:3048-3059.
46. Stein MB, Sareen J. Clinical practice: generalized anxiety disorder. N Engl J Med. 2015;373:2059-2068.
47. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317:1358-1367.
48. Leichsenring F, Leweke F. Social anxiety disorder. N Engl J Med. 2017;376:2255-2264.
49. Moon W, Kim SN, Park S, et al. The cost-effectiveness of deep brain stimulation for patients with treatment-resistant obsessive-compulsive disorder. Medicine (Baltimore). 2017;96:1-8.
50. Kim SJ, Roh D, Jung HH, et al. A study of novel bilateral thermal capsulotomy with focused ultrasound for treatment-refractory obsessive-compulsive disorder: 2-year follow-up. J Psychiatry Neurosci. 2018;43:327-337.
51. Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017;376:2459-2469.
52. Addington D, Abidi S, Garcia-Ortega I, et al. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. Can J Psychiatry. 2017;62:594-603.
53. Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379:270-280.
54. Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62:604-616.
55. Clark LA, Nuzum H, Ro E. Manifestations of personality impairment severity: comorbidity, course/prognosis, psychosocial dysfunction, and ‘borderline’ personality features. Curr Opin Psychol. 2017;21:117-121.
56. Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet. 2016;387:1227-1239.
57. Stephens G, Derry S, Moore RA. Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2016;6:CD011889.
58. Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2017;1:CD011888.
59. Derry S, Wiffen PJ, Moore RA, Bendtsen L. Ibuprofen for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2015;7:CD011474.
60. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev. 2016;4:CD008541.
61. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(suppl 4):221-235.
62. Friedman BW, Irizarry E, Solorzano C, et al. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017;89:2075-2082.
63. Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;82:976-983.
64. Yarnitsky D, Volokh L, Ironi A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88:1250-1255.
65. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21:973-989.
66. Bruloy E, Sinna R, Grolleau JL, et al. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg. 2019;143:239-250.
67. Schoenen JE. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2016;86:201-202.
68. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-434.
69. Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132.
70. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113-2122.
71. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999-2008.
72. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080-1088.
73. Jackson JL, Mancuso JM, Nickoloff S, et al. Tricyclic and tetracyclic antidepressants for the prevention of frequent episodic or chronic tension-type headache in adults: a systematic review and meta-analysis. J Gen Intern Med. 2017;32:1351-1358.
74. Zhao L, Chen J, Li Y, et al. The long-term effect of acupuncture for migraine prophylaxis: a randomized clinical trial. JAMA Intern Med. 2017;177:508-515.
75. Petersen AS, Barloese MC, Lund NL, et al. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia. 2017;37:214-224.
76. Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56:1317-1332.
77. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317-328.
78. Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311:1641-1651.
79. Bruce BB, Digre KB, McDermott MP, et al. Quality of life at 6 months in the idiopathic intracranial hypertension treatment trial. Neurology. 2016;87:1871-1877.
80. Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48:856-866.
81. Comara MS, Mart?n Bujanda M, Mendioroz Iriarte M. Epigenetic changes in headache. Neurologia. 2017. [Epub ahead of print.]
82. Tabatabai RR, Swadron SP. Headache in the emergency department: avoiding misdiagnosis of dangerous secondary causes. Emerg Med Clin North Am. 2016;34:695-716.
83. Probyn K, Bowers H, Caldwell F, et al. Prognostic factors for chronic headache: a systematic review. Neurology. 2017;89:291-301.
84. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17:174-182.
85. Dodick DW. Migraine. Lancet. 2018;391:1315-1330.
86. Charles A. Migraine. N Engl J Med. 2017;377:553-561.
87. Maasumi K, Michael RL, Rapoport AM. CGRP and migraine: the role of blocking calcitonin gene-related peptide ligand and receptor in the management of migraine. Drugs. 2018;78:913-928.
88. Jensen RH. Tension-type headache—the normal and most prevalent headache. Headache. 2018;58:339-345.
89. Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17:75-83.
90. Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: the American Headache Society evidence-based guidelines. Headache. 2016;56:1093-1106.
91. Rizzoli P, Mullally WJ. Headache. Am J Med. 2018;131:17-24.
92. Munksgaard SB, Madsen SK, Wienecke T. Treatment of medication overuse headache—a review. Acta Neurol Scand. 2019;139:405-414.
93. Fisayo A, Bruce BB, Newman NJ, et al. Overdiagnosis of idiopathic intracranial hypertension. Neurology. 2016;86:341-350.
94. Dinkin MJ, Patsalides A. Venous sinus stenting in idiopathic intracranial hypertension: results of a prospective trial. J Neuroophthalmol. 2017;37:113-121.
95. Kranz PG, Malinzak MD, Amrhein TJ, et al. Update on the diagnosis and treatment of spontaneous intracranial hypotension. Curr Pain Headache Rep. 2017;21:1-8.
96. Gaiser RR. Postdural puncture headache: an evidence-based approach. Anesthesiol Clin. 2017;35:157-167.
97. Cruccu G. Trigeminal neuralgia. Continuum (Minneap Minn). 2017;23:396-420.
98. Ramusino MC, Perini G, Antonaci F, et al. The treatment of trigeminal autonomic cephalalgias: an overview. J Oral Facial Pain Headache. 2019;33:89-104.
99. Zhang D, Xue Q, Chen J, et al. Decompressive craniectomy in the management of intracranial hypertension after traumatic brain injury: a systematic review and meta-analysis. Sci Rep. 2017;7:1-10.
100. Lewis SR, Evans DJ, Butler AR, et al. Hypothermia for traumatic brain injury. Cochrane Database Syst Rev. 2017;9:CD001048.
101. Thomas DG, Apps JN, Hoffmann RG, et al. Benefits of strict rest after acute concussion: a randomized controlled trial. Pediatrics. 2015;135:213-223.
102. Cooper DB, Bowles AO, Kennedy JE, et al. Cognitive rehabilitation for military service members with mild traumatic brain injury: a randomized clinical trial. J Head Trauma Rehabil. 2017;32:E1-E15.
103. Lee DY, Park YJ, Kim HJ, et al. Early surgical decompression within 8 hours for traumatic spinal cord injury: is it beneficial? A meta-analysis. Acta Orthop Traumatol Turc. 2018;52:101-108.
104. Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80:533-539.
105. Feddermann-Demont N, Echemendia RJ, Schneider KJ, et al. What domains of clinical function should be assessed after sport-related concussion? A systematic review. Br J Sports Med. 2017;51:903-918.
106. McCrory P, Meeuwisse W, Dvo??k J, et al. Consensus statement on concussion in sport—the 5(th) international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017;51:838-847.
107. Mondello S, Sorinola A, Czeiter E, et al. Blood-based protein biomarkers for the management of traumatic brain injuries in adults presenting with mild head injury to emergency departments: a living systematic review and meta-analysis. J Neurotrauma. 2017;34:1-21.
108. Easter JS, Haukoos JS, Meehan WP, et al. Will neuroimaging reveal a severe intracranial injury in this adult with minor head trauma? The rational clinical examination systematic review. JAMA. 2015;314:2672-2681.
109. Carney N, Totten AM, O’Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80:6-15.
110. Williamson C, Morgan L, Klein JP. Imaging in neurocritical care practice. Semin Respir Crit Care Med. 2017;38:840-852.
111. Badhiwala JH, Lai CK, Alhazzani W, et al. Cervical spine clearance in obtunded patients after blunt traumatic injury: a systematic review. Ann Intern Med. 2015;162:429-437.
112. Polieu I, Kull C, Walder B. Prehospital and emergency care in adult patients with acute traumatic brain injury. Med Sci (Basel). 2019;7:1-14.
113. Geeraerts T, Velly L, Abdennour L, et al. Management of severe traumatic brain injury (first 24 hours). Anaesth Crit Care Pain Med. 2018;37:171-186.
114. Marshall S, Bayley M, McCullagh S, et al. Updated clinical practice guidelines for concussion/mild traumatic brain injury and persistent symptoms. Brain Inj. 2015;29:688-700.
115. Kurowski BG, Hugentobler J, Quatman-Yates C, et al. Aerobic exercise for adolescents with prolonged symptoms after mild traumatic brain injury: an exploratory randomized clinical trial. J Head Trauma Rehabil. 2017;32:79-89.
116. Ruschel J, Hellal F, Flynn KC, et al. Axonal regeneration. Systemic administration of epothilone B promotes axon regeneration after spinal cord injury. Science. 2015;348:347-352.
117. Yue JK, Winkler EA, Rick JW, et al. Update on critical care for acute spinal cord injury in the setting of polytrauma. Neurosurg Focus. 2017;34:1-21.
118. Lavis T, Goetz LL. Comprehensive care for persons with spinal cord injury. Phys Med Rehabil Clin N Am. 2019;30:55-72.
119. Squair JW, B?langer LM, Tsang A, et al. Spinal cord perfusion pressure predicts neurologic recovery in acute spinal cord injury. Neurology. 2017;89:1660-1667.
120. Steward KA, Gerstenecker A, Triebel KL, et al. Twelve-month recovery of medical decision-making capacity following traumatic brain injury. Neurology. 2016;87:1052-1059.
121. Barnes DE, Byers AL, Gardner RC, et al. Association of mild traumatic brain injury with and without loss of consciousness with dementia in US military veterans. JAMA Neurol. 2018;75:1055-1061.
122. Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318:360-370.
123. Schaffert J, LoBue C, White CL, et al. Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer’s disease. Neuropsychology. 2018;32:410-416.
124. Ziegler G, Grabher P, Thompson A, et al. Progressive neurodegeneration following spinal cord injury: implications for clinical trials. Neurology. 2018;90:e1257-e1266.
125. Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166:480-492.
126. Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:1-13.
127. Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319:872-882.
128. Chou R, Deyo R, Friedly J, et al. Nonpharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166:493-505.
129. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:514-530.
130. Hedlund R, Johansson C, Hagg O, et al. The long-term outcome of lumbar fusion in the Swedish lumbar spine study. Spine J. 2016;16:579-587.
131. Mannion AF, Brox JI, Fairbank JC. Comparison of spinal fusion and nonoperative treatment in patients with chronic low back pain: long-term follow-up of three randomized controlled trials. Spine J. 2013;13:1438-1448.
132. Steffens D, Maher CG, Pereira LS, et al. Prevention of low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016;176:199-208.
133. Delitto A, Piva SR, Moore CG, et al. Surgery versus nonsurgical treatment of lumbar spinal stenosis: a randomized trial. Ann Intern Med. 2015;162:465-473.
134. Friedly JL, Comstock BA, Turner JA, et al. A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med. 2014;371:11-21.
135. Forsth P, ?lafsson G, Carlsson T, et al. A randomized, controlled trial of fusion surgery for lumbar spinal stenosis. N Engl J Med. 2016;374:1413-1423.
136. Ghogawala Z, Dziura J, Butler WE, et al. Laminectomy plus fusion versus laminectomy alone for lumbar spondylolisthesis. N Engl J Med. 2016;374:1424-1434.
137. Machado GC, Maher CG, Ferreira PH, et al. Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Ann Rheum Dis. 2017;76:1269-1278.
138. Mathieson S, Maher CG, McLachlan AJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376:1111-1120.
139. Chou R, Hashimoto R, Friedly J, et al. Epidural corticosteroid injections for radiculopathy and spinal stenosis: a systematic review and meta-analysis. Ann Intern Med. 2015;163:373-381.
140. Bicket MC, Horowitz JM, Benzon HT, et al. Epidural injections in prevention of surgery for spinal pain: systematic review and meta-analysis of randomized controlled trials. Spine J. 2015;15:348-362.
141. Phan K, Xu J, Schultz K, et al. Full-endoscopic versus micro-endoscopic and open discectomy: a systematic review and meta-analysis of outcomes and complications. Clin Neurol Neurosurg. 2017;154:1-12.
142. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017;389:736-747.
143. Ropper AH, Zafonte RD. Sciatica. N Engl J Med. 2015;372:1240-1248.
144. Verhagen AP, Downie A, Popal N, et al. Red flags presented in current low back pain guidelines: a review. Eur Spine J. 2016;25:2788-2802.
145. Johnson SM, Shah LM. Imaging of acute low back pain. Radiol Clin North Am. 2019;57:397-413.
146. Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391:2368-2383.
147. Yamada K, Satoh S, Abe Y, et al. Diffuse idiopathic skeletal hyperostosis extended to the lumbar segment is a risk factor of reoperation in patients treated surgically for lumbar stenosis. Spine. 2018;43:1446-1453.
148. Fehlings MG, Tetreault LA, Wilson JR, et al. A clinical practice guideline for the management of acute spinal cord injury: introduction, rationale, and scope. Global Spine J. 2017;7:84s-94s.
149. Badhiwala JH, Wilson JR. The natural history of degenerative cervical myelopathy. Neurosurg Clin N Am. 2018;29:21-32.
150. Amin RM, Andrade NS, Neuman BJ. Lumbar disc herniation. Curr Rev Musculoskelet Med. 2017;10:507-516.
151. Lawton AJ, Lee KA, Cheville AL, et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019;37:61-71.
152. Ropper AE, Ropper AH. Acute spinal cord compression. N Engl J Med. 2017;376:1358-1369.
153. Zalewski NL, Rabinstein AA, Krecke KN, et al. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurol. 2019;76:56-63.
154. Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology. 2018;90:e96-e102.
155. Fehlings MG, Nater A, Tetreault L, et al. Survival and clinical outcomes in surgically treated patients with metastatic epidural spinal cord compression: results of the prospective multicenter AOSpine study. J Clin Oncol. 2016;34:268-276.
156. Breitenstein C, Grewe T, Floel A, et al. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet. 2017;389:1528-1538
157. Arena JE, Rabinstein AA. Transient global amnesia. Mayo Clin Proc. 2015;90:264-272
158. Binder JR. Current controversies on Wernicke’s area and its role in language. Curr Neurol Neurosci Rep. 2017;17:1-10
159. Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. J Neurol. 2018;265:1474-1490
160. Tee BL, Gorno-Tempini ML. Primary progressive aphasia: a model for neurodegenerative disease. Curr Opin Neurol. 2019;32:255-265
161. Casella G, Llinas RH, Marsh EB. Isolated aphasia in the emergency department: the likelihood of ischemia is low. Clin Neurol Neurosurg. 2017;163:24-26
162. De Simoni S, Jenkins PO, Bourke NJ, et al. Altered caudate connectivity is associated with executive dysfunction after traumatic brain injury. Brain. 2018;141:148-164
163. Kane RL, Butler M, Fink HA, et al. AHRQ Comparative Effectiveness Reviews. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017.
164. Tricco AC, Ashoor HM, Soobiah C, et al. Comparative effectiveness and safety of cognitive enhanc­ers for treating Alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66:170-178.
165. Renn BN, Asghar-Ali AA, Thielke S, et al. A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatry. 2018;26:134-147.
166. Farina N, Llewellyn D, Isaac M, et al. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017;4:CD002854.
167. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311:33-44.
168. Grodstein F, O’Brien J, Kang JH, et al. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med. 2013;159:806-814.
169. Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378:321-330.
170. Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2018;378:1691-1703.
171. Atri A, Frolich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018;319:130-142.
172. Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med. 2019;380:1408-1420.
173. Lamb SE, Sheehan B, Atherton N, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ. 2018;361:1-11.
174. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86:135-143.
175. Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of dementia over three decades in the Fram­ingham heart study. N Engl J Med. 2016;374:523-532.
176. Wolters FJ, van der Lee SJ, Koudstaal PJ, et al. Parental family history of dementia in relation to subclinical brain disease and dementia risk. Neurology. 2017;88:1642-1649.
177. Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017;13:457-476.
178. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016;1:CD011145.
179. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:126-135.
180. Sanders AE, Nininger J, Absher J, et al. Quality improvement in neurology: dementia management quality measurement set update. Neurology. 2017;88:1951-1957.
181. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388:505-517.
182. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological defini­tion of Alzheimer’s disease. Alzheimers Dement. 2018;14:535-562.
183. Bature F, Guinn BA, Pang D, et al. Signs and symptoms preceding the diagnosis of Alzheimer’s disease: a systematic scoping review of literature from 1937 to 2016. BMJ Open. 2017;7:1-9.
184. Sheikh-Bahaei N, Sajjadi SA, Pierce AL. Current role for biomarkers in clinical diagnosis of Alzheimer disease and frontotemporal dementia. Curr Treat Options Neurol. 2017;19:1-20.
185. Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—a systematic review. Eur J Radiol. 2017;94:16-24.
186. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cogni­tive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255-2263.
187. Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377-389.
188. O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698-1706.
189. Armstrong MJ. Lewy body dementias. Continuum (Minneap Minn). 2019;25:128-146.
190. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100.17. H?glinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853-864.
191. Espay AJ, Da Prat GA, Dwivedi AK, et al. Deconstructing normal pressure hydrocephalus: ventricu­lomegaly as early sign of neurodegeneration. Ann Neurol. 2017;82:503-513.
192. O’Connor CM, Landin-Romero R, Clemson L, et al. Behavioral-variant frontotemporal dementia: distinct phenotypes with unique functional profiles. Neurology. 2017;89:570-577.
193. Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919-931.
194. Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35:339-374.
195. Deleon J, Miller BL. Frontotemporal dementia. Handb Clin Neurol. 2018;148:409-430.
196. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84:1705-1713.
197. Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;12:CD011412.
198. Hu Q, Zhang F, Teng W, et al. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis. J Neurol. 2018;265:1-11.
199. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153-2163.
200. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020.
201. Thiele EA, Marsh ED, French JA, et al; GWPCARE Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085-1096.
202. Jobst BC, Cascino GD. Resective epilepsy surgery for drug-resistant focal epilepsy: a review. JAMA. 2015;313:285-293.
203. Fiest KM, Sajobi TT, Wiebe S. Epilepsy surgery and meaningful improvements in quality of life: results from a randomized controlled trial. Epilepsia. 2014;55:886-892.
204. Dwivedi R, Ramanujam B, Chandra PS, et al. Surgery for drug-resistant epilepsy in children. N Engl J Med. 2017;377:1639-1647.
205. Sprengers M, Vonck K, Carrette E, et al. Deep brain and cortical stimulation for epilepsy. Cochrane Database Syst Rev. 2017;7:CD008497.
206. Barbaro NM, Quigg M, Ward MM, et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: the randomized, controlled ROSE trial. Epilepsia. 2018;59:1198-1207.
207. Legriel S, Lemiale V, Schenck M, et al. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med. 2016;375:2457-2467.
208. Pohlmann-Eden B, Marson AG, Noack-Rink M, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol. 2016;16:1-12.
209. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522-530.
210. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296-303.
211. Weber YG, Biskup S, Helbig KL, et al. The role of genetic testing in epilepsy diagnosis and management. Expert Rev Mol Diagn. 2017;17:739-750.
212. Marsan E, Baulac S. Review: mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. Neuropathol Appl Neurobiol. 2018;44:6-17.
213. Fisher RS, Cross JH, D’Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531-542.
214. Johnson EL. Seizures and epilepsy. Med Clin North Am. 2019;103:309-324.
215. Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393:689-701.
216. Milon-Tomos A, Persyko M, Del Campo M, et al. An overview of psychogenic non-epileptic seizures: etiology, diagnosis and management. Can J Neurol Sci. 2018;45:130-136.
217. Kunze A, Reuber M. The first seizure as an indicator of epilepsy. Curr Opin Neurol. 2018;31:156-161.
218. Tao JX, Davis AM. Management of an unprovoked first seizure in adults. JAMA. 2016;316:1590-1591.
219. Gavvala JR, Schuele SU. New-onset seizure in adults and adolescents: a review. JAMA. 2016;316:2657-2668.
220. Engel J Jr. The current place of epilepsy surgery. Curr Opin Neurol. 2018;31:192-197.
221. Vakharia VN, Duncan JS, Witt JA, et al. Getting the best outcomes from epilepsy surgery. Ann Neurol. 2018;83:676-690.
222. Veroniki AA, Cogo E, Rios P, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15:1-20.
223. Lamberink HJ, Otte WM, Geerts AT, et al. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. Lancet Neurol. 2017;16:523-531.
224. Keezer MR, Bell GS, Neligan A, et al. Cause of death and predictors of mortality in a community-based cohort of people with epilepsy. Neurology. 2016;86:704-712.
225. Gorton HC, Webb RT, Carr MJ, et al. Risk of unnatural mortality in people with epilepsy. JAMA Neurol. 2018;75:928-938.
226. Sperling MR, Barshow S, Nei M, et al. A reappraisal of mortality after epilepsy surgery. Neurology. 2016;86:1938-1944.
227. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016;375:1119-1130.
228. Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819-826.
229. Cooksley T, Rose S, Holland M. A systematic approach to the unconscious patient. Clin Med (Lond). 2018;18:88-92.
230. Wijdicks EF. Management of the comatose patient. Handb Clin Neurol. 2017;140:117-129.
231. Geocadin RG, Wijdicks E, Armstrong MJ, et al. Practice guideline summary: reducing brain injury following cardiopulmonary resuscitation: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2017;88:2141-2149.
232. Westhall E, Rossetti AO, van Rootselaar AF, et al. Standardized EEG interpretation accurately predicts prognosis after cardiac arrest. Neurology. 2016;86:1482-1490.
233. Kondziella D, Friberg CK, Frokjaer VG, et al. Preserved consciousness in vegetative and minimal conscious states: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87:485-492.
234. Ragazzoni A, Cincotta M, Giovannelli F, et al. Clinical neurophysiology of prolonged disorders of consciousness: from diagnostic stimulation to therapeutic neuromodulation. Clin Neurophysiol. 2017;128:1629-1646.
235. Fins JJ, Bernat JL. Ethical, palliative, and policy considerations in disorders of consciousness. Neurology. 2018;91:471-475.
236. Eapen BC, Georgekutty J, Subbarao B, et al. Disorders of consciousness. Phys Med Rehabil Clin N Am. 2017;28:245-258.
237. Giacino JT, Katz DI, Schiff ND, et al. Comprehensive systematic review update summary: disorders of consciousness: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. 2018;91:461-470.
238. Giacino JT, Katz DI, Schiff ND, et al. Practice guideline update recommendations summary: disorders of consciousness: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. 2018;91:450-460.
239. Mattogno PP, Barbagallo G, Iacopino G, et al. Recovery from chronic diseases of consciousness: state of the art in neuromodulation for persistent vegetative state and minimally conscious state. Acta Neurochir Suppl. 2017;124:19-25.
240. Lewis A, Greer D. Current controversies in brain death determination. Nat Rev Neurol. 2017;13:505-509.
241. Russell JA, Epstein LG, Greer DM, et al. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. Neurology. 2019;92:228-304.
242. Dauvilliers Y, Roth T, Guinta D, et al. Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med. 2017;40:53-57
243. Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85:359-370
244. Philip P, Chaufton C, Taillard J, et al. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. Sleep. 2014; 37:483-487
245. Corral J, S?nchez-Quiroga M?, Carmona-Bernal C, et al. Conventional polysomnography is not necessary for the management of most patients with suspected obstructive sleep apnea. Noninfe­riority, randomized controlled trial. Am J Respir Crit Care Med. 2017;196:1181-1190
246. Howard ME, Piper AJ, Stevens B, et al. A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome. Thorax. 2017;72:437-444
247. Masa JF, Mokhlesi B, Benitez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet. 2019;393:1721-1732
248. Yu J, Zhou Z, McEvoy RD, et al. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and meta-analysis. JAMA. 2017;318:156-166
249. Schwartz M, Acosta L, Hung YL, et al. Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnea patients: a systematic review and meta-analysis. Sleep Breath. 2018;22:555-568
250. Woodson BT, Soose RJ, Gillespie MB, et al. Three-year outcomes of cranial nerve stimulation for obstructive sleep apnea: the STAR trial. Otolaryngol Head Neck Surg. 2016;154:181-188
251. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095-1105
252. Costanzo MR, Ponikowski P, Javaheri S, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet. 2016;388:974-982
253. Ritterband LM, Thorndike FP, Ingersoll KS, et al. Effect of a web-based cognitive behavior therapy for insomnia intervention with 1-year follow-up: a randomized clinical trial. JAMA Psychiatry. 2017;74:68-75
254. Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 2016;12:1215-1225
255. Manber R, Buysse DJ, Edinger J, et al. Efficacy of cognitive-behavioral therapy for insomnia combined with antidepressant pharmacotherapy in patients with comorbid depression and insomnia: a ran­domized controlled trial. J Clin Psychiatry. 2016;77:e1316-e1323.
256. Garcia-Borreguero D, Allen R, Hudson J, et al. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study. Curr Med Res Opin. 2016;32:77-85
257. Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621-631
258. Deng Y, Wu J, Jia Q. Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo-controlled study. Med Sci Monit. 2017;23:1254-1260
259. Mukherjee S, Patel SR, Kales SN, et al. An official American Thoracic Society statement: the impor­tance of healthy sleep. Recommendations and future priorities. Am J Respir Crit Care Med. 2015;191:1450-1458
260. Westwood AJ, Beiser A, Jain N, et al. Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology. 2017;88:1172-1179
261. Oberle D, Pavel J, Mayer G, et al. Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. Sleep Med. 2017;34:71-83
262. Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39-57
263. Bosi M, De Vito A, Kotecha B, et al. Phenotyping the pathophysiology of obstructive sleep apnea using polygraphy/polysomnography: a review of the literature. Sleep Breath. 2018;22:579-592
264. Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health. 2018;8:1-10
265. Youssef I, Kamran H, Yacoub M, et al. Obstructive sleep apnea as a risk factor for atrial fibrillation: a meta-analysis. J Sleep Disord Ther. 2018;7:1-10
266. Jonas DE, Amick HR, Feltner C, et al. Screening for obstructive sleep apnea in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317:415-433
267. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13:479-504
268. Veasey SC, Rosen IM. Obstructive sleep apnea in adults. N Engl J Med. 2019;380:1442-1449.
269. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675-700
270. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13:307-349
271. Pavlova M. Circadian rhythm sleep-wake disorders. Continuum (Minneap Minn). 2017;23:1051-1063
272. Lyall LM, Wyse CA, Graham N, et al. Association of disrupted circadian rhythmicity with mood disorders, subjective wellbeing, and cognitive function: a cross-sectional study of 91 105 participants from the UK Biobank. Lancet Psychiatry. 2018;5:507-514
273. St Louis EK, Boeve BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc. 2017;92:1723-1736
274. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87:2585-2593
275. RoffeC, NevatteT, SimJ, etal. Effect of routine low-dose oxygen supplementation on death and disability in adults with acute stroke: the stroke oxygen study randomized clinical trial. JAMA. 2017;318:1125-1135.
276. Hakim SM, Ammar MA, Reyad MS. Effect of therapeutic hypothermia on survival and neurological outcome in adults suffering cardiac arrest: a systematic review and meta-analysis. Minerva Anestesiol. 2018;84:720-730.
277. Kim F, Nichol G, Maynard C, et al. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: a randomized clinical trial. JAMA. 2014;311:45-52.
278. Lilja G, Nielsen N, Friberg H, et al. Cognitive function in survivors of out-of-hospital cardiac arrest after target temperature management at 33 degrees C versus 36 degrees C. Circulation. 2015;131: 1340-1349.
279. Hankey GJ. Stroke. Lancet. 2017;389:641-654.
280. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update. Circulation. 2019;139:e56-e528.
281. Feigin VL, Nguyen G, Cercy K, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379:2429-2437.
282. Murphy SL, Xu J, Kochanek KD, et al. Deaths: final data for 2015. Natl Vital Stat Rep. 2017;66:1-75.
283. Gorelick PB, Furie KL, Iadecola C, et al. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. Stroke. 2017;48:e284-e303.
284. Theodorakis PE, M?ller EA, Craster RV, et al. Physical insights into the blood-brain barrier translocation mechanisms. Phys Biol. 2017;14:1-25.
285. Chan PS, Berg RA, Tang Y, et al. Association between therapeutic hypothermia and survival after in-hospital cardiac arrest. JAMA. 2016;316:1375-1382.
286. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46-e110.
287. EbingerM, WinterB, WendtM, etal. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014;311:1622-1631.
288. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935.
289. Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380:1795-1803.
290. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20.
291. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030.
292. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296-2306.
293. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-1018.
294. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285-2295.
295. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723-1731.
296. van den Berg LA, Dijkgraaf MG, Berkhemer OA, et al. Two-year outcome after endovascular treatment for acute ischemic stroke. N Engl J Med. 2017;376:1341-1349.
297. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708-718.
298. Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573-1582.
299. Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388:365-375.
300. Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391:850-859.
301. He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479-489.
302. Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet. 2019;393:877-888.
303. Misra UK, Kalita J, Chandra S, et al. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol. 2012;19:1030-1036.
304. Markus HS, Levi C, King A, et al. Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the cervical artery dissection in stroke study (CADISS) randomized clinical trial final results. JAMA Neurol. 2019;76:657-664.
305. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467-2477.
306. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380:1906-1917.
307. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378:2191-2201.
308. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313:1325-1335.
309. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-515.
310. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39:1172-1180.
311. Orrapin S, Rerkasem K. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev. 2017;6:CD001081.
312. Brott TG, Howard G, Roubin GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med. 2016;374:1021-1031.
313. Rosenfield K, Matsumura JS, Chaturvedi S, et al. Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J Med. 2016;374:1011-1020.
314. Howard G, Roubin GS, Jansen O, et al. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet. 2016;387:1305-1311.
315. De Rosa S, Sievert H, Sabatino J, et al. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: a systematic review and meta-analysis. Ann Intern Med. 2018;168:343-350.
316. Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383:333-341.
317. Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313:1240-1248.
318. Markus HS, Larsson SC, Kuker W, et al. Stenting for symptomatic vertebral artery stenosis: the vertebral artery ischaemia stenting trial. Neurology. 2017;89:1229-1236.
319. BenjaminEJ, MuntnerP, AlonsoA, etal. Heart disease and stroke statistics-2019 update. Circulation. 2019;139:e56-e528.
320. Hankey GJ. Stroke. Lancet. 2017;389:641-654.
321. Pride GL, Fraser JF, Gupta R, et al. Prehospital care delivery and triage of stroke with emergent large vessel occlusion (ELVO): report of the Standards and Guidelines Committee of the Society of Neurointerventional Surgery. J Neurointerv Surg. 2017;9:802-812.
322. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46-e110.
323. Zerna C, Thomalla G, Campbell BCV, et al. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. Lancet. 2018;392:1247-1256.
324. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581-641.
325. Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316:1279-1288.
326. Miller CM, Behrouz R. Impact of infection on stroke morbidity and outcomes. Curr Neurol Neurosci Rep. 2016;16:1-5.
327. Ferro JM, Bousser MG, Canhao P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24:1203-1213.
328. Bougea A, Spantideas N. Vasculitis in the central nervous system. Adv Exp Med Biol. 2017;1003:173-185.
329. Katsanos AH, Bhole R, Frogoudaki A, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology. 2016;87:988-995.
330. Saver JL. Clinical practice: cryptogenic stroke. N Engl J Med. 2016;374:2065-2074.
331. Gittler M, Davis AM. Guidelines for adult stroke rehabilitation and recovery. JAMA. 2018;319:820-821.
332. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e116-e135.
333. Bress AP, Kramer H, Khatib R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey). Circulation. 2017;135:1617-1628.
334. Najib N, Magin P, Lasserson D, et al. Contemporary prognosis of transient ischemic attack patients: a systematic review and meta-analysis. IntJStroke. 2019. [Epub ahead of print.]
335. Gaberel T, Magheru C, Emery E, et al. Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis. ActaNeurochir (Wien). 2012;154:1-9.
336. Mutoh T, Kazumata K, Terasaka S, et al. Early intensive versus minimally invasive approach to postoperative hemodynamic management after subarachnoid hemorrhage. Stroke. 2014;45:1280-1284.
337. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebralhaematomas (STICH II): a randomised trial. Lancet. 2013;382:397-408.
338. Hanley DF, Lane K, McBee N, et al. Thrombolytic removal of intraventricularhaemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017;389:603-611.
339. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243.
340. Baharoglu MI, Cordonnier C, Salman RA, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387:2605-2613.
341. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-2365.
342. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-1043.
343. Sprigg N, Flaherty K, Appleton JP, et al. Tranexamic acid for hyperacute primary intracerebralhaemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391:2107-2115.
344. Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383:614-621.
345. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage.Lancet. 2017;389:655-666.
346. Nurmonen HJ, Huttunen T, Huttunen J, et al. Polycystic kidney disease among 4,436 intracranial aneurysm patients from a defined population. Neurology. 2017;89:1852-1859.
347. Lawton MT, Vates GE. Subarachnoid hemorrhage.N Engl J Med. 2017;377:257-266.
348. Perry JJ, Sivilotti MLA, Sutherland J, et al. Validation of the Ottawa Subarachnoid Hemorrhage Rule in patients with acute headache. CMAJ. 2017;189:e1379-e1385.
349. Perry JJ, Alyahya B, Sivilotti ML, et al. Differentiation between traumatic tap and aneurysmal sub­arachnoid hemorrhage: prospective cohort study. BMJ. 2015;350:1-7.
350. Cho WS, Kim JE, Park SQ, et al. Korean clinical practice guidelines for aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2018;61:127-166.
351. Francoeur CL, Roh D, Schmidt JM, et al. Desmopressin administration and rebleeding in subarachnoid hemorrhage: analysis of an observational prospective database. J Neurosurg. 2018;1-7.
352. Feng R, Mascitelli J, Chartrain AG, et al. Anti-epileptic drug (AED) use in subarachnoid hemorrhage (SAH) and intracranial hemorrhage (ICH). Curr Pharm Des. 2017;23:6446-6453.
353. Pal’a A, Schneider M, Brand C, et al. The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia-continuous selective intracarotidnimodipine therapy in awake patients without sedation.Neurosurg Rev. 2019;42:463-469.
354. Alotaibi NM, Wang JZ, Pasarikovski CR, et al. Management of raised intracranial pressure in aneurysmal subarachnoid hemorrhage: time for a consensus? Neurosurg Focus. 2017;43:1-8.
355. Malhotra A, Wu X, Forman HP, et al. Growth and rupture risk of small unruptured intracranial aneurysms: a systematic review. Ann Intern Med. 2017;167:26-33.
356. Gross BA, Jankowitz BT, Friedlander RM. Cerebral intraparenchymal hemorrhage: a review. JAMA. 2019;321:1295-1303.
357. Cordonnier C, Demchuk A, Ziai W, et al. Intracerebralhaemorrhage: current approaches to acute management. Lancet. 2018;392:1257-1268.
358. Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intra­cranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care. 2016;24:6-46.
359. Tsai HH, Kim JS, Jouvent E, et al. Updates on prevention of hemorrhagic and lacunar strokes. J Stroke. 2018;20:167-179.
360. Taslimi S, Modabbernia A, Amin-Hanjani S, et al. Natural history of cavernous malformation: systematic review and meta-analysis of 25 studies. Neurology. 2016;86:1984-1991.
361. Nikolaev SI, Vetiska S, Bonilla X, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med. 2018;378:250-261.
362. Solomon RA, Connolly ES Jr. Arteriovenous malformations of the brain. N Engl J Med. 2017;376:1859-1866.
363. Rafferty MR, Prodoehl J, Robichaud JA, et al. Effects of 2 years of exercise on gait impairment in people with Parkinson disease: the PRET-PD randomized trial. J Neurol Phys Ther. 2017;41: 21-30.
364. Mak MK, Wong-Yu IS, Shen X, et al. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol. 2017;13:689-703.
365. Chen F, Jin L, Nie Z. Safety and efficacy of rotigotine for treating Parkinson’s disease: a meta-analysis of randomised controlled trials. J Pharm Sci. 2017;20:285-294.
366. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664-1675.
367. Xie CL, Zhang YY, Wang XD, et al. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis. Neurol Sci. 2015;36:1319-1329.
368. Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med. 2019;380:315-324.
369. Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196-1205.
370. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12:346-356.
371. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141-149.
372. Wilby KJ, Johnson EG, Johnson HE, et al. Evidence-based review of pharmacotherapy used for Parkinson’s disease psychosis. Ann Pharmacother. 2017;51:682-695.
373. Tan ZG, Zhou Q, Huang T, et al. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson’s disease: a meta-analysis of randomized controlled trials. Clin Interv Aging. 2016;11:777-786.
374. Gardner RC, Byers AL, Barnes DE, et al. Mild TBI and risk of Parkinson disease: a Chronic Effects of Neurotrauma Consortium study. Neurology. 2018;90:e1771-e1779.
375. Racette BA, Searles Nielsen S, Criswell SR, et al. Dose-dependent progression of parkinsonism in manganese-exposed welders. Neurology. 2017;88:344-351.
376. Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2018;42:72-85.
377. Liu G, Locascio JJ, Corvol JC, et al. Prediction of cognition in Parkinson’s disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 2017;16:620-629.
378. Brundin P, Melki R. Prying into the prion hypothesis for Parkinson’s disease. J Neurosci. 2017;37:9808-9818.
379. Mittal S, Bjornevik K, Im DS, et al. ?2-adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357:891-898.
380. Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33:75-87.
381. Fasano A, Canning CG, Hausdorff JM, et al. Falls in Parkinson’s disease: a complex and evolving picture. Mov Disord. 2017;32:1524-1536.
382. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease–an evidence-based medicine review. Mov Disord. 2019;34:180-198.
383. Getz SJ, Levin B. Cognitive and neuropsychiatric features of early Parkinson’s disease. Arch Clin Neuropsychol. 2017;32:769-785.
384. Reich SG, Savitt JM. Parkinson’s disease. Med Clin North Am. 2019;103:337-350.
385. Laurencin C, Danaila T, Broussolle E, et al. Initial treatment of Parkinson’s disease in 2016: the 2000 consensus conference revisited. Rev Neurol (Paris). 2016;172:512-523.
386. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896-912.
387. Antonini A, Moro E, Godeiro C, et al. Medical and surgical management of advanced Parkinson’s disease. Mov Disord. 2018;33:900-908.
388. Weaver FM, Stroupe KT, Smith B, et al. Survival in patients with Parkinson’s disease after deep brain stimulation or medical management. Mov Disord. 2017;32:1756-1763.
389. Bruno E, Nicoletti A, Quattrocchi G, et al. Topiramate for essential tremor. Cochrane Database Syst Rev. 2017;4:CD009683.
390. Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016;375:730-739.
391. Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316:40-50.
392. Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114.
393. Hainque E, Vidailhet M, Cozic N, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016;86:1729-1735.
394. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003-2010.
395. Kume A. Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose? Neuropsychiatr Dis Treat. 2014;10:249-262.
396. Benussi A, Dell’Era V, Cantoni V, et al. Cerebello-spinal tDCS in ataxia: a randomized, double-blind, sham-controlled, crossover trial. Neurology. 2018;91:e1090-e1101.
397. Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33:75-87.
398. Reich SG. Essential tremor. Med Clin North Am. 2019;103:351-356.
399. Haubenberger D, Hallett M. Essential tremor. N Engl J Med. 2018;378:1802-1810.
400. Ferreira JJ, Mestre TA, Lyons KE, et al. MDS evidence-based review of treatments for essential tremor. Mov Disord. 2019. [Epub ahead of print.]
401. Nance MA. Genetics of Huntington disease. Handb Clin Neurol. 2017;144:3-14.
402. McCusker EA, Loy CT. Medical management of motor manifestations of Huntington disease. Handb Clin Neurol. 2017;144:141-150.
403. Mestre TA, Shannon K. Huntington disease care: from the past to the present, to the future. Parkinsonism Relat Disord. 2017;44:114-118.
404. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington’s disease. N Engl J Med. 2019. [Epub ahead of print.]
405. Mencacci NE, Erro R, Wiethoff S, et al. ADCY5 mutations are another cause of benign hereditary chorea. Neurology. 2015;85:80-88.
406. Santens P, Van Damme T, Steyaert W, et al. RNF216 mutations as a novel cause of autosomal recessive Huntington-like disorder. Neurology. 2015;84:1760-1766.
407. Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018;18:51-63.
408. Jinnah HA, Hess EJ. Evolving concepts in the pathogenesis of dystonia. Parkinsonism Relat Disord. 2018;46(suppl 1):S62-S65.
409. Zech M, Jech R, Havrankova P, et al. KMT2B rare missense variants in generalized dystonia. Mov Disord. 2017;32:1087-1091.
410. Erro R, Tinazzi M, Morgante F, et al. Non-invasive brain stimulation for dystonia: therapeutic impli­cations. Eur J Neurol. 2017;24:1228-e1241.
411. Huang AY, Yu D, Davis LK, et al. Rare copy number variants in NRXN1 and CNTN6 increase risk for Tourette syndrome. Neuron. 2017;94:1101-1111.
412. Pringsheim T, Okun MS, M?ller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92:896-906.
413. Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome—new therapeutic option. Neurol Neurochir Pol. 2018;52:84-87.
414. Eberhardt O, Topka H. Myoclonic disorders. Brain Sci. 2017;7:1-26.
415. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136-1147.
416. Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199-204.
417. Trotti LM. Restless legs syndrome and sleep-related movement disorders. Continuum (Minneap Minn). 2017;23:1005-1016.
418. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2016;87:2585-2593.
419. Ondo W. Deep brain stimulation (DBS) for severe restless legs syndrome: therapeutic and physiologic considerations. Sleep Med. 2017;31:93-94.
420. Maas RP, van Gaalen J, Klockgether T, et al. The preclinical stage of spinocerebellar ataxias. Neurology. 2015;85:96-103.
421. de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, et al. Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum. 2017;16:525-551.
422. Bork K. Friedreich ataxia: current status and future prospects. Cerebellum Ataxias. 2017;4:1-9.
423. Sun YM, Lu C, Wu ZY. Spinocerebellar ataxia: relationship between phenotype and genotype—a review. Clin Genet. 2016;90:305-314.
424. Teive HAG, Camargo CHF, Munhoz RP. More than ataxia — movement disorders in ataxia-telangiectasia. Parkinsonism Relat Disord. 2018;46:3-8.
425. Manes M, Alberici A, Di Gregorio E, et al. Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38. Ann Neurol. 2017;82:615-621.
426. Liu S, Liu X, Chen S, et al. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: a meta-analysis of randomized controlled trials. PLoS ONE. 2017;12:1-13.
427. Melendez-Torres GJ, Auguste P, Armoiry X, et al. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technol Assess. 2017;21:1-352.
428. La Mantia L, Di Pietrantonj C, Rovaris M, et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016;11:CD009333.
429. Saida T, Kira JI, Kishida S, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017;11:25-31.
430. Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405-415.
431. Zhang J, Shi S, Zhang Y, et al. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2017;11:CD010968.
432. Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;5:CD002127.
433. La Mantia L, Tramacere I, Firwana B, et al. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016;4:CD009371.
434. He D, Zhang C, Zhao X, et al. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev. 2016;3:CD009882.
435. Xu Z, Zhang F, Sun F, et al. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev. 2015;4:CD011076.
436. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209-220.
437. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221-234.
438. Castillo-Trivino T, Braithwaite D, Bacchetti P, et al. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS ONE. 2013;8:1-8.
439. Comi G, Cook S, Rammohan K, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord. 2018;11:1-11.
440. Jensen HB, Nielsen JL, Ravnborg M, et al. Effect of slow release-fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Mult Scler Relat Disord. 2016;10:137-144.
441. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263-1273.
442. Metz LM, Li DKB, Traboulsee AL, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;376:2122-2133.
443. Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol. 2018;75:690-696.
444. Galetta KM, Bhattacharyya S. Multiple sclerosis and autoimmune neurology of the central nervous system. Med Clin North Am. 2019;103:325-336.
445. Zurawski J, Stankiewicz J. Multiple sclerosis re-examined: essential and emerging clinical concepts. Am J Med. 2018;131:464-472.
446. Томпсон А.Дж., Бануэлл Б. Л., Баркхоф Ф. и др. Диагностика рассеянного склероза: пересмотр критериев МакДональда в 2017 году. Lancet Neurol. 2018;17:162-173.
447. Giorgio A, De Stefano N. Effective utilization of MRI in the diagnosis and management of multiple sclerosis. Neurol Clin. 2018;36:27-34.
448. Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391:1622-1636.
449. Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study. Neurology. 2016;87:1393-1399.
450. Siva A. Common clinical and imaging conditions misdiagnosed as multiple sclerosis: a current approach to the differential diagnosis of multiple sclerosis. Neurol Clin. 2018;36:69-117.
451. Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2017;17:530-536.
452. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777-788.
453. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:789-800.
454. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169-180.
455. Vidal-Jordana A. New advances in disease-modifying therapies for relapsing and progressive forms of multiple sclerosis. Neurol Clin. 2018;36:173-183.
456. Burkill S, Montgomery S, Hajiebrahimi M, et al. Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012. Neurology. 2017;89:555-562.
457. Kale N. Optic neuritis as an early sign of multiple sclerosis. Eye Brain. 2016;8:195-202.
458. Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology. 2018;90:e96-e102.
459. Patterson SL, Goglin SE. Neuromyelitis optica. Rheum Dis Clin North Am. 2017;43:579-591.
460. Etemadifar M, Salari M, Mirmosayyeb O, et al. Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci. 2017;22:1-7.
461. van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134:351-382.
462. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377:1630-1638.
463. Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016;388:476-487.
464. Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83:166-177.
465. Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378:840-851.
466. McCracken L, Zhang J, Greene M, et al. Improving the antibody-based evaluation of autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4:1-7.
467. Harutyunyan G, Hauer L, Dunser MW, et al. Autoimmune encephalitis at the neurological intensive care unit: etiologies, reasons for admission and survival. Neurocrit Care. 2017;27:82-89.
468. Solnes LB, Jones KM, Rowe SP, et al. Diagnostic value of (18)F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis. J Nucl Med. 2017;58:1307-1313.
469. Wang Y, Liu X, Wang Y, et al. Meta-analysis of adjunctive dexamethasone to improve clinical outcome of bacterial meningitis in children. Childs Nerv Syst. 2018;34:217-223.
470. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol. 2010;9:254-263.
471. Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;9:CD004405.
472. Fritz D, Brouwer MC, van de Beek D. Dexamethasone and long-term survival in bacterial meningitis. Neurology. 2012;79:2177-2179.
473. Aurelius E, Franzen-R?hl E, Glim?ker M, et al. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. Clin Infect Dis. 2012;54:1304-1313.
474. Heemskerk AD, Bang ND, Mai NT, et al. Intensified antituberculosis therapy in adults with tuber­culous meningitis. N Engl J Med. 2016;374:124-134.
475. Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin Infect Dis. 2017;65:20-28.
476. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:CD002244.
477. Day JN, Chau TTH, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291-1302.
478. Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated crypto­coccal meningitis. N Engl J Med. 2016;374:542-554.
479. Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningi­tis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis. 2016;16:339-347.
480. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64:e34-e65.
481. Sulaiman T, Salazar L, Hasbun R. Acute versus subacute community-acquired meningitis: analysis of 611 patients. Medicine (Baltimore). 2017;96:1-6.
482. Tracy A, Waterfield T. How to use clinical signs of meningitis. Arch Dis Child Educ Pract Ed. 2019. [Epub ahead of print.]
483. Glim?ker M, Sj?lin J, ?kesson S, et al. Lumbar puncture performed promptly or after neuroimaging in acute bacterial meningitis in adults: a prospective national cohort study evaluating different guidelines. Clin Infect Dis. 2018;66:321-328.
484. McGill F, Heyderman RS, Panagiotou S, et al. Acute bacterial meningitis in adults. Lancet. 2016;388:3036-3047.
485. Akkaya O, Guvenc HI, Yuksekkaya S, et al. Real-time PCR detection of the most common bacteria and viruses causing meningitis. Clin Lab. 2017;63:827-832.
486. Bortcosh W, Siedner M, Carroll RW. Utility of the urine reagent strip leucocyte esterase assay for the diagnosis of meningitis in resource-limited settings: meta-analysis. Trop Med Int Health. 2017;22:1072-1080.
487. Hasbun R, Rosenthal N, Balada-Llasat JM, et al. Epidemiology of meningitis and encephalitis in the United States, 2011-2014. Clin Infect Dis. 2017;65:359-363.van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. Clin Microbiol Infect. 2017;23:601-606.
488. McGill F, Heyderman RS, Michael BD, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. J Infect. 2016;72:405-438.
489. McGill F, Griffiths MJ, Solomon T. Viral meningitis: current issues in diagnosis and treatment. Curr Opin Infect Dis. 2017;30:248-256.
490. Bookstaver PB, Mohorn PL, Shah A, et al. Management of viral central nervous system infections: a primer for clinicians. J Cent Nerv Syst Dis. 2017;9:1-12.
491. Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13:581-598.
492. Rios-Sarabia N, Hernandez-Gonzalez O, Gonzalez YMJ, et al. Identification of Mycobacterium tuberculosis in the cerebrospinal fluid of patients with meningitis using nested PCR. Int J Mol Med. 2016;38:1289-1295.
493. Pormohammad A, Riahi SM, Nasiri MJ, et al. Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: a systematic review and meta-analysis. J Infect. 2017;74:545-554.
494. de Almeida SM, de Souza CV, Pletsch L, et al. Diagnostic importance of eosinophilic meningitis in HIV-positive and HIV-negative patients. J Neurovirol. 2019. [Epub ahead of print.]
495. Ong CT, Tsai CF, Wong YS, et al. Epidemiology of brain abscess in Taiwan: a 14-year population-based cohort study. PLoS ONE. 2017;12:1-10.
496. Laulajainen Hongisto A, Aarnisalo AA, Lempinen L, et al. Otogenic intracranial abscesses, our experience over the last four decades. J Int Adv Otol. 2017;13:40-46.
497. Boother EJ, Brownlow S, Tighe HC, et al. Cerebral abscess associated with odontogenic bacteremias, hypoxemia, and iron loading in immunocompetent patients with right-to-left shunting through pulmonary arteriovenous malformations. Clin Infect Dis. 2017;65:595-603.
498. Sonneville R, Ruimy R, Benzonana N, et al. An update on bacterial brain abscess in immunocompetent patients. Clin Microbiol Infect. 2017;23:614-620.
499. Madhuripan N, Hicks RJ, Feldmann E, et al. A protocol-based approach to spinal epidural abscess imaging improves performance and facilitates early diagnosis. J Am Coll Radiol. 2018;15:648-651.
500. Brouwer MC, van de Beek D. Management of bacterial central nervous system infections. Handb Clin Neurol. 2017;140:349-364.
501. Bodilsen J, Brouwer MC, Nielsen H, et al. Anti-infective treatment of brain abscess. Expert Rev Anti Infect Ther. 2018;16:565-578.
502. Brook I. Microbiology and treatment of brain abscess. J Clin Neurosci. 2017;38:8-12.
503. Vakili M, Crum-Cianflone NF. Spinal epidural abscess: a series of 101 cases. Am J Med. 2017;130:1458-1463.
504. Ropper AE, Ropper AH. Acute spinal cord compression. N Engl J Med. 2017;376:1358-1369.
505. Babic M, Simpfendorfer CS, Berbari EF. Update on spinal epidural abscess. Curr Opin Infect Dis. 2019;32:265-271.
506. Stratton A, Gustafson K, Thomas K, et al. Incidence and risk factors for failed medical management of spinal epidural abscess: a systematic review and meta-analysis. J Neurosurg Spine. 2017;26:81-89.
507. Lener S, Hartmann S, Barbagallo GMV, et al. Management of spinal infection: a review of the literature. Acta Neurochir (Wien). 2018;160:487-496.
508. Khatri IA, Wasay M. Septic cerebral venous sinus thrombosis. J Neurol Sci. 2016;362:221-227.
509. Cantier M, Mazighi M, Klein I, et al. Neurologic complications of infective endocarditis: recent findings. Curr Infect Dis Rep. 2017;19:41.
510. Venkatesan A, Michael BD, Probasco JC, et al. Acute encephalitis in immunocompetent adults. Lancet. 2019;393:702-716.
511. Tyler KL. Acute viral encephalitis. N Engl J Med. 2018;379:557-566.
512. Musoz LS, Garcia MA, Gordon-Lipkin E, et al. Emerging viral infections and their impact on the global burden of neurological disease. Semin Neurol. 2018;38:163-175.
513. Reid S, Thompson H, Thakur KT. Nervous system infections and the global traveler. Semin Neurol. 2018;38:247-262.
514. Liesman RM, Strasburg AP, Heitman AK, et al. Evaluation of a commercial multiplex molecular panel for diagnosis of infectious meningitis and encephalitis. J ClinMicrobiol. 2018;56:1-9.
515. Salzberg SL, Breitwieser FP, Kumar A, et al. Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system. NeurolNeuroimmunolNeuroinflamm. 2016;3:1-9.
516. Ellul M, Solomon T. Acute encephalitis—diagnosis and management. Clin Med (Lond). 2018;18:155-159.
517. Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83:166-177.
518. Rabinstein AA. Herpes virus encephalitis in adults: current knowledge and old myths. NeurolClin. 2017;35:695-705.
519. Freire de Carvalho M, Vigilato MAN, Pompei JA, et al. Rabies in the Americas: 1998-2014. PLoSNegl Trop Dis. 2018;12:1-16.
520. Fooks AR,Cliquet F, Finke S, et al. Rabies. Nat Rev Dis Primers. 2017;3:1-19.
521. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390:1511-1520.
522. Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nat Rev Genet. 2018;19:405-418.
523. Latest NCJDRSU CJD monthly statistics. Natl CJD Res Surveill Unit Data Reports. https://www.cjd.ed.ac.uk/surveillance/data-and-reports. Accessed July 3, 2019.
524. Ae R, Hamaguchi T, Nakamura Y, et al. Update: dura mater graft-associated Creutzfeldt-Jakob disease—Japan, 1975-2017. MMWR Morb Mortal Wkly Rep. 2018;67:274-278.
525. Crowder LA, Schonberger LB, Dodd RY, et al. Creutzfeldt-Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk. Transfusion. 2017;57:1875-1878.
526. Erana H. The Prion 2018 round tables (II): Abeta, tau, alpha-synuclein… are they prions, prion-like proteins, or what? Prion. 2019;13:41-45.
527. Takada LT, Kim MO, Metcalf S, et al. Prion disease. HandbClin Neurol. 2018;148:441-464.
528. Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann. Neurol. 2017;81:79-92.
529. Grim J, Ticha A, Hyspler R, et al. Selected risk nutritional factors for chemotherapy-induced polyneuropathy. Nutrients. 2017;9:1-10.
530. O’Brien PD, Hinder LM, Callaghan BC, et al. Neurological consequences of obesity. Lancet Neurol. 2017;16:465-477.
531. Punchai S, Hanipah ZN, Meister KM, et al. Neurologic manifestations of vitamin B deficiency after bariatric surgery. Obes Surg. 2017;27:2079-2082.
532. Nilles EJ, Manaia A, Ruaia B, et al. Re-emergence of thiamine deficiency disease in the Pacific islands (2014-15): a case-control study. PLoS ONE. 2018;13:E1-E14.
533. Isenberg-Grzeda E, Alici Y, Hatzoglou V, et al. Nonalcoholic thiamine-related encephalopathy (Wernicke-Korsakoff syndrome) among inpatients with cancer: a series of 18 cases. Psychosomatics. 2016;57:71-81.
534. Oudman E, Wijnia JW, van Dam M, et al. Preventing Wernicke encephalopathy after bariatric surgery. Obes Surg. 2018;28:2060-2068.
535. Shah IA, Asimi RP, Kawoos Y, et al. Nonalcoholic Wernicke’s encephalopathy: a retrospective study from a tertiary care center in northern India. J Neurosci Rural Pract. 2017;8:401-406.
536. Chamorro AJ, Roson-Hernandez B, Medina-Garcia JA, et al. Differences between alcoholic and nonalcoholic patients with Wernicke encephalopathy: a multicenter observational study. Mayo Clin Proc. 2017;92:899-907.
537. Logan C, Asadi H, Kok HK, et al. Neuroimaging of chronic alcohol misuse. J Med Imaging Radiat Oncol. 2017;61:435-440.
538. Polegato BF, Pereira AG, Azevedo PS, et al. Role of thiamin in health and disease. Nutr Clin Pract. 2019. [Epub ahead of print.]
539. Sanvisens A, Zuluaga P, Fuster D, et al. Long-term mortality of patients with an alcohol-related Wernicke-Korsakoff syndrome. Alcohol Alcohol. 2017;52:466-471.
540. Porter K, Hoey L, Hughes CF, et al. Causes, consequences and public health implications of low B-vitamin status in ageing. Nutrients. 2016;8:1-29.
541. Ma F, Wu T, Zhao J, et al. Plasma homocysteine and serum folate and vitamin B12 levels in mild cognitive impairment and Alzheimer’s disease: a case-control study. Nutrients. 2017;9:1-11.
542. Luthe SK, Sato R. Alcoholic pellagra as a cause of altered mental status in the emergency department. J Emerg Med. 2017;53:554-557.
543. Shi H, Enriquez A, Rapadas M, et al. NAD deficiency, congenital malformations, and niacin supplementation. N Engl J Med. 2017;377:544-552.
544. Wysota B, Michael S, Hiew FL, et al. Severe but reversible neuropathy and encephalopathy due to vitamin E deficiency. Clin Neurol Neurosurg. 2017;160:19-20.
545. Hammoud N, Jimenez-Shahed J. Chronic neurologic effects of alcohol. Clin Liver Dis. 2019;23:141-155.
546. Brown JM, Bland R, Jonsson E, et al. The standardization of diagnostic criteria for fetal alcohol spectrum disorder (FASD): implications for research, clinical practice and population health. Can J Psychiatry. 2018;1-8.
547. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817-824.
548. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153-2163.
549. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125-132.
550. Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol. 2018;154:773-780.
551. Hong SJ, Bernhardt BC, Caldairou B, et al. Multimodal MRI profiling of focal cortical dysplasia type II. Neurology. 2017;88:734-742.
552. Segel R, Ben-Pazi H, Zeligson S, et al. Copy number variations in cryptogenic cerebral palsy. Neurol­ogy. 2015;84:1660-1668.
553. Nahm NJ, Graham HK, Gormley ME Jr, et al. Management of hypertonia in cerebral palsy. Curr Opin Pediatr. 2018;30:57-64.
554. Romero DM, Bahi-Buisson N, Francis F. Genetics and mechanisms leading to human cortical malformations. Semin Cell Dev Biol. 2018;76:33-75.
555. Poretti A, Boltshauser E, Huisman TA. Cerebellar and brainstem malformations. Neuroimaging Clin N Am. 2016;26:341-357.
556. Khalsa SSS, Geh N, Martin BA, et al. Morphometric and volumetric comparison of 102 children with symptomatic and asymptomatic Chiari malformation Type I. J Neurosurg Pediatr. 2018;21:65-71.
557. Langridge B, Phillips E, Choi D. Chiari malformation type 1: a systematic review of natural history and conservative management. World Neurosurg. 2017;104:213-219.
558. Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:1-19.
559. Jain A, Marshall J, Buikema A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. 2015;313:1534-1540.
560. Velikonja T, Fett AK, Velthorst E. Patterns of nonsocial and social cognitive functioning in adults with autism spectrum disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2019. [Epub ahead of print.]
561. Lord C, Elsabbagh M, Baird G, et al. Autism spectrum disorder. Lancet. 2018;392:508-520.
562. Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:1-17.
563. Uusitalo E, Rantanen M, Kallionpaa RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34:1978-1986.
564. Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550-2560.
565. Halliday J, Rutherford SA, McCabe MG, et al. An update on the diagnosis and treatment of vestibular schwannoma. Expert Rev Neurother. 2018;18:29-39.
566. Randle SC. Tuberous sclerosis complex: a review. Pediatr Ann. 2017;46:e166-e171.
567. Rosser T. Neurocutaneous disorders. Continuum (Minneap Minn). 2018;24:96-129.
568. Dornbos D 3rd, Kim HJ, Butman JA, et al. Review of the neurological implications of von Hippel-Lindau disease. JAMA Neurol. 2018;75:620-627.
569. Jonasch E, McCutcheon IE, Gombos DS, et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19:1351-1359.
570. Izcovich A, Gonzalez Malla C, Manzotti M, et al. Midodrine for orthostatic hypotension and recurrent reflex syncope: a systematic review. Neurology. 2014;83:1170-1177.
571. Strassheim V, Newton JL, Tan MP, et al. Droxidopa for orthostatic hypotension: a systematic review and meta-analysis. J Hypertens. 2016;34:1933-1941.
572. Schreglmann SR, Buchele F, Sommerauer M, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease—a randomized controlled trial. Eur J Neurol. 2017;24:545-551.
573. Byun JI, Moon J, Kim DY, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology. 2017;89:1078-1086.
574. Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23:178-183.
575. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11-21.
576. Smart KM, Wand BM, O’Connell NE. Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst Rev. 2016;2:CD010853.
577. Goebel A, Bisla J, Carganillo R, et al. Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome: a randomized trial. Ann Intern Med. 2017;167:476-483.
578. Cheshire WP Jr. Syncope. Continuum (Minneap Minn). 2017;23:335-358.
579. Goldberger JJ, Arora R, Buckley U, et al. Autonomic nervous system dysfunction: JACC focus seminar. J Am Coll Cardiol. 2019;73:1189-1206.
580. Cheshire WP Jr. Thermoregulatory disorders and illness related to heat and cold stress. Auton Neurosci. 2016;196:91-104.
581. Guo L, Esler MD, Sari C, et al. Does sympathetic dysfunction occur before denervation in pure autonomic failure? Clin Sci. 2018;132:1-16.
582. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372:249-263.
583. Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci. 2018;211:15-25.
584. Ruelle L, Bentea G, Sideris S, et al. Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature part 4: neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer. 2017;111:150-163.
585. Koike H, Nakamura T, Hashizume A, et al. Cardiac and peripheral vasomotor autonomic func­tions in late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol. 2017;264:2293-2302.
586. Baker J, Racosta JM, Kimpinski K. Comparison of heart rate variability parameters to the autonomic reflex screen in postural orthostatic tachycardia syndrome and neurogenic orthostatic hypotension. J Clin Neurophysiol. 2018;35:115-122.
587. Sone D. Small fiber neuropathy: diagnosis, causes, and treatment. Joint Bone Spine. 2018;85:553-555.
588. Biaggioni I. The pharmacology of autonomic failure: from hypotension to hypertension. Pharmacol Rev. 2017;69:53-62.
589. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screen­ing, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hyperten­sion. J Neurol. 2017;264:1567-1582.
590. Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81:287-297.
591. Ricci F, Manzoli L, Sutton R, et al. Hospital admissions for orthostatic hypotension and syncope in later life: insights from the Malm? Preventive Project. J Hypertens. 2017;35:776-783.
592. Goh EL, Chidambaram S, Ma D. Complex regional pain syndrome: a recent update. Burns Trauma. 2017;5:1-14.
593. Petersen PB, Mikkelsen KL, Lauritzen JB, et al. Risk factors for post-treatment complex regional pain syndrome (CRPS): an analysis of 647 Cases of CRPS from the Danish Patient Compensation Association. Pain Pract. 2018;18:341-349.
594. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2:CD001447.
595. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512.
596. Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86:1474-1481.
597. Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurother. 2017;14:762-772.
598. Restivo DA, Casabona A, Nicotra A, et al. ALS dysphagia pathophysiology: differential botulinum toxin response. Neurology. 2013;80:616-620.
599. Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/ motor neuron disease. Cochrane Database Syst Rev. 2017;10:CD004427.
600. Gonzalez-Bermejo J, Mor?lot-Panzini C, Tanguy ML, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15:1217-1227.
601. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723-1732.
602. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625-635.
603. Foster LA, Salajegheh MK. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med. 2019;132:32-37.
604. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084-2098.
605. Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:1-19.
606. Bidhendi EE, Bergh J, Zetterstrom P, et al. Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease. J Clin Invest. 2016;126:2249-2253.
607. Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identi­fies risk genes and pathways. Science. 2015;347:1436-1441.
608. Gibson SB, Downie JM, Tsetsou S, et al. The evolving genetic risk for sporadic ALS. Neurology. 2017;89:226-233.
609. Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919-931.
610. Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302-2309.
611. Britton D, Karam C, Schindler JS. Swallowing and secretion management in neuromuscular disease. Clin Chest Med. 2018;39:449-457.
612. Braun AT, Caballero-Eraso C, Lechtzin N. Amyotrophic lateral sclerosis and the respiratory system. Clin Chest Med. 2018;39:391-400.
613. Brown RH Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162-172.
614. Polkey MI, Lyall RA, Yang K, et al. Respiratory muscle strength as a predictive biomarker for survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2017;195:86-95.
615. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713-1722.
616. Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355-368.
617. Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24:194-204.
618. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11-21.
619. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22-31.
620. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658-2667.
621. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr? syndrome. Cochrane Database Syst Rev. 2014;9:CD002063.
622. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barr? syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.
623. Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain-Barr? syndrome. Cochrane Database Syst Rev. 2016;10:CD001446.
624. Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;11:CD002062.
625. Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1:CD010369.
626. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10:CD002827.
627. Dy SM, Bennett WL, Sharma R, et al. AHRQ Comparative Effectiveness Reviews. Preventing complications and treating symptoms of diabetic peripheral neuropathy. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017. https://www.ncbi.nlm.nih.gov/books/NBK442335/pdf/Bookshelf_NBK442335.pdf. Accessed May 29, 2019.
628. Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 2017;88:1958-1967.
629. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.
630. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-1032.
631. Smith EM, Pang H, Ye C, et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial—CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017;26:1-19.
632. Chesterton LS, Blagojevic-Bucknall M, Burton C, et al. The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial. Lancet. 2018;392:1423-1433.
633. Wu YT, Ke MJ, Ho TY, et al. Randomized double-blinded clinical trial of 5% dextrose versus triamcinolone injection for carpal tunnel syndrome patients. Ann Neurol. 2018;84:601-610.
634. Madhok VB, Gagyor I, Daly F, et al. Corticosteroids for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2016;7:CD001942.
635. Gagyor I, Madhok VB, Daly F, et al. Antiviral treatment for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2015;11:CD001869.
636. Barrell K, Smith AG. Peripheral neuropathy. Med Clin North Am. 2019;103:383-397.
637. Hanewinckel R, Drenthen J, van Oijen M, et al. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology. 2016;87:1892-1898.
638. Jones MR, Urits I, Wolf J, et al. Drug-induced peripheral neuropathy, a narrative review. Curr Clin Pharmacol. 2019. [Epub ahead of print.]
639. Ramchandren S. Charcot-Marie-Tooth disease and other genetic polyneuropathies. Continuum (Minneap Minn). 2017;23:1360-1377.
640. Plante-Bordeneuve V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol. 2018;265:976-983.
641. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barr? syndrome. Lancet. 2016;388:717-727.
642. Donofrio PD. Guillain-Barr? syndrome. Continuum (Minneap Minn). 2017;23:1295-1309.
643. Zheng X, Yu L, Xu Q, et al. Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review. BMC Infect Dis. 2018;18:1-8.
644. Nascimento OJM, da Silva IRF. Guillain-Barr? syndrome and Zika virus outbreaks. Curr Opin Neurol. 2017;30:500-507.
645. Lewis RA. Chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol. 2017;30:508-512.
646. Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve. 2018;57:875-883.
647. Delmont E, Manso C, Querol L, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017;140:1851-1858.
648. Jongbloed BA, Haakma W, Goedee HS, et al. Comparative study of peripheral nerve MRI and ultrasound in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. 2016;54:1133-1135.
649. Kumar A, Patwa HS, Nowak RJ. Immunoglobulin therapy in the treatment of multifocal motor neuropathy. J Neurol Sci. 2017;375:190-197.
650. Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017;13:302-316.
651. Mauermann ML. The peripheral neuropathies of POEMS syndrome and Castleman disease. Hematol Oncol Clin North Am. 2018;32:153-163.
652. Dispenzieri A. POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:814-829.
653. Delmont E, Hiew FL, Cassereau J, et al. Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study. J Peripher Nerv Syst. 2017;22:27-33.
654. Lancaster E. Paraneoplastic disorders. Continuum (Minneap Minn). 2017;23:1653-1679.
655. Vinik AI. Clinical practice: diabetic sensory and motor neuropathy. N Engl J Med. 2016;374:1455-1464.
656. Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8:646-655.
657. Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81:772-781.
658. Hamel J, Logigian EL. Acute nutritional axonal neuropathy. Muscle Nerve. 2018;57:33-39.
659. Van Eijk JJ, Groothuis JT, Van Alfen N. Neuralgic amyotrophy: an update on diagnosis, pathophysiol­ogy, and treatment. Muscle Nerve. 2016;53:337-350.
660. Calandruccio JH, Thompson NB. Carpal tunnel syndrome: making evidence-based treatment decisions. Orthop Clin North Am. 2018;49:223-229.
661. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123-2131
662. McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489-1498
663. Silva MC, Magalhaes TA, Meira ZM, et al. Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial. JAMA Cardiol. 2017;2:190-199
664. Statland JM, Bundy BN, Wang Y, et al. Mexiletine for symptoms and signs of myotonia in nondys­trophic myotonia: a randomized controlled trial. JAMA. 2012;308:1357-1365
665. Sansone VA, Burge J, McDermott MP, et al. Randomized, placebo-controlled trials of dichlorphena­mide in periodic paralysis. Neurology. 2016;86:1408-1416
666. Case LE, Bjartmar C, Morgan C, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord. 2015;25:321-332
667. Bird TD, Smith CO. Clinical approach to the patient with neurogenetic disease. Handb Clin Neurol. 2018;147:3-9
668. Schorling DC, Kirschner J, Bonnemann CG. Congenital muscular dystrophies and myopathies: an overview and update. Neuropediatrics. 2017;48:247-261
669. McNally EM, Kaltman JR, Benson DW, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation. 2015;131:1590-1598
670. Randeree L, Eslick GD. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: a pooled-analysis. J Clin Neurosci. 2018;49:1-6
671. Bach JR. Noninvasive respiratory management of patients with neuromuscular disease. Ann Rehabil Med. 2017;41:519-538
672. Nakamura A. Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy. J Hum Genet. 2017;62:871-876
673. Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expres­sion in a mouse model of muscular dystrophy. Science. 2016;351:400-403
674. Koeks Z, Bladen CL, Salgado D, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4:293-306
675. DeSimone AM, Pakula A, Lek A, et al. Facioscapulohumeral muscular dystrophy. Compr Physiol. 2017;7:1229-1279
676. Wood L, Cordts I, Atalaia A, et al. The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. J Neurol. 2017;264:979-988
677. Thornton CA, Wang E, Carrell EM. Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev. 2017;44:135-140
678. Mathis S, Tazir M, Magy L, et al. History and current difficulties in classifying inherited myopathies and muscular dystrophies. J Neurol Sci. 2018;384:50-54
679. Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57:522-530
680. Ghaoui R, Sue CM. Movement disorders in mitochondrial disease. J Neurol. 2018;265:1230-1240
681. Heighton JN, Brady LI, Newman MC, et al. Clinical and demographic features of chronic progressive external ophthalmoplegia in a large adult-onset cohort. Mitochondrion. 2019;44:15-19
682. Simon L, Jolley SE, Molina PE. Alcoholic myopathy: pathophysiologic mechanisms and clinical implications. Alcohol Res. 2017;38:207-217
683. Nazir S, Lohani S, Tachamo N, et al. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017;23:149-154
684. Minetto MA, D’Angelo V, Arvat E, et al. Diagnostic work-up in steroid myopathy. Endocrine. 2018;60:219-223
685. Domingo-Horne RM, Salajegheh MK. An approach to myopathy for the primary care clinician. Am J Med. 2018;131:237-243
686. Meyer A, Sibilia J. Strategy for suspected myositis. Joint Bone Spine. 2019. (Epub ahead of print.)
687. Clark KEN, Isenberg DA. A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol. 2018;25:13-23
688. Schmidt K, Schmidt J. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Curr Opin Rheumatol. 2017;29:632-638
689. Kramer CL. Intensive care unit-acquired weakness. Neurol Clin. 2017;35:723-736
690. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277.
691. Wolfe GI, Kaminski HJ, Cutter GR. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:2006-2007.
692. Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18:259-268.
693. Wang L, Zhang S, Xi J, et al. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2017;264:2191-2200.
694. Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87:57-64.
695. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976-986.
696. Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53:717-725.
697. Sanders DB, Juel VC, Harati Y, et al. 3,4-Diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018;57:561-568.
698. Bettini M, Chaves M, Cristiano E, et al. Incidence of autoimmune myasthenia gravis in a health maintenance organization in Buenos Aires, Argentina. Neuroepidemiology. 2017;48:119-123.
699. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128-136.
700. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570-2581.
701. Roper J, Fleming ME, Long B, et al. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med. 2017;53:843-853.
702. Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci. 2018;1413:143-153.
703. Sussman J, Farrugia ME, Maddison P, et al. The Association of British Neurologists’ myasthenia gravis guidelines. Ann N Y Acad Sci. 2018;1412:166-169.
704. Tandan R, Hehir MK 2nd, Waheed W, et al. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56:185-196.
705. Evoli A. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 2017;30:464-470.
706. Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1-16.
707. Abenroth DC, Smith AG, Greenlee JE, et al. Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve. 2017;56:421-426.
708. Schoser B, Eymard B, Datt J, et al. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017;264:1854-1863.
709. Oh SJ. Distinguishing features of the repetitive nerve stimulation test between Lambert-Eaton myasthenic syndrome and myasthenia gravis, 50-year reappraisal. J Clin Neuromuscul Dis. 2017;19:66-75.
710. Bauche S, O’Regan S, Azuma Y, et al. Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. Am J Hum Genet. 2016;99:753-761.
711. Aran A, Segel R, Kaneshige K, et al. Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome. Neurology. 2017;88:1021-1028.
712. Shieh PB, Oh SJ. Congenital myasthenic syndromes. Neurol Clin. 2018;36:367-378.

Труды отечественных авторов при подготовке статей по терапии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.

- Вернуться в оглавление раздела "Терапия"

Редактор: Искандер Милевски. Дата обновления публикации: 15.6.2025